U.S. patent application number 15/447007 was filed with the patent office on 2018-02-01 for stable crystal of 4-oxoquinoline compound.
This patent application is currently assigned to Japan Tobacco Inc.. The applicant listed for this patent is Japan Tobacco Inc.. Invention is credited to Koji ANDO, Kentaro KONDO, Koji MATSUDA, Takashi MATSUDA, Shuji MIYAKE, Takahisa MOTOMURA, Motohide SATOH, Hideto UEHARA.
Application Number | 20180029989 15/447007 |
Document ID | / |
Family ID | 35079161 |
Filed Date | 2018-02-01 |
United States Patent
Application |
20180029989 |
Kind Code |
A1 |
SATOH; Motohide ; et
al. |
February 1, 2018 |
STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND
Abstract
Provision of a stabilized crystal of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A
crystal of compound A, which shows a particular X-ray powder
diffraction pattern of a characteristic diffraction peaks at
diffraction angles 2.theta.(.degree.) as measured by X-ray powder
diffractmetry.
Inventors: |
SATOH; Motohide; (Osaka,
JP) ; MOTOMURA; Takahisa; (Osaka, JP) ;
MATSUDA; Takashi; (Osaka, JP) ; KONDO; Kentaro;
(Osaka, JP) ; ANDO; Koji; (Osaka, JP) ;
MATSUDA; Koji; (Osaka, JP) ; MIYAKE; Shuji;
(Osaka, JP) ; UEHARA; Hideto; (Osaka, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Japan Tobacco Inc. |
Tokyo |
|
JP |
|
|
Assignee: |
Japan Tobacco Inc.
Tokyo
JP
|
Family ID: |
35079161 |
Appl. No.: |
15/447007 |
Filed: |
March 1, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14593946 |
Jan 9, 2015 |
|
|
|
15447007 |
|
|
|
|
12538694 |
Aug 10, 2009 |
8981103 |
|
|
14593946 |
|
|
|
|
11133471 |
May 20, 2005 |
7635704 |
|
|
12538694 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 215/56 20130101;
A61P 31/00 20180101; A61P 31/18 20180101 |
International
Class: |
C07D 215/56 20060101
C07D215/56 |
Foreign Application Data
Date |
Code |
Application Number |
May 20, 2004 |
JP |
2004-150979 |
Claims
1. A crystal of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an X-ray
powder diffraction pattern having characteristic diffraction peaks
at diffraction angles 2.theta. of 6.56.degree., 13.20.degree.,
19.86.degree., 20.84.degree., 21.22.degree., 25.22.degree. as
measured by X-ray powder diffractometer.
2-6. (canceled)
7. A mixed crystal comprising a crystal of
6-{3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an X-ray
powder diffraction pattern having characteristic diffraction peaks
at diffraction angles 2.theta. of 6.56.degree., 13.20.degree.,
19.86.degree., 20.84.degree., 21.22.degree., 25.22.degree. as
measured by X-ray powder diffractometer, and at least one crystal
selected from: a crystal of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an X-ray
powder diffraction pattern having characteristic diffraction peaks
at diffraction angles 2.theta. of 8.54.degree., 14.02.degree.,
15.68.degree., 17.06.degree., 17.24.degree., 24.16.degree.,
25.74.degree. as measured by X-ray powder diffractometer; and a
crystal of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an
extrapolated onset temperature of 162.1.+-.5.0.degree. C.
8. (canceled)
9. A pharmaceutical composition comprising the crystal of claim 1
and a pharmaceutically acceptable carrier.
10-12. (canceled)
13. An anti-HIV composition comprising the mixed crystal of claim 7
and one or more kinds of other anti-HIV active substances as active
ingredients.
14. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority under 35
U.S.C. .sctn. 119(a) to JP 2004-150979 filed May 20, 2004, which is
incorporated herein by reference.
TECHNICAL FIELD
[0002] The present invention relates to a stable crystal of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
##STR00001##
(hereinafter sometimes to be compound A) and a mixed crystal
thereof. The present invention also relates to a pharmaceutical
composition comprising the crystal or the mixed crystal.
BACKGROUND ART
[0003] The present Applicant has disclosed in Japanese Patent
Application No. 2003-293117 filed by the same Applicant that the
above-mentioned compound A has an inhibitory action on integrase
that is an en essential enzyme for the growth of HIV (Human
Immunodeficiency Virus), which is a causative virus of AIDS
(Acquired Immunodeficiency Syndrome), and shows an anti-HIV effect
(particularly Example 4-32 and Experimental Example).
[0004] In general, when a compound is used as a pharmaceutical
product, chemical and physical stability of the compound is
required so as to maintain quality and/or facilitate preservation.
Not only the final pharmaceutical composition but also a compound
as a synthetic starting material is desirably chemically and
physically stable for the same reasons.
[0005] Therefore, such compound is preferably a crystal,
particularly preferably a stable crystal. When the compound has
crystal polymorphism, the most stable crystal is generally
selected.
[0006] While the above-mentioned application describes compound A,
no concrete description relating to the crystal form of compound A
is found.
SUMMARY OF THE INVENTION
[0007] Thus, the present inventors have studied various crystal
forms of compound A in an attempt to find a stable crystal of
compound A. As a result, they have found that compound A has
crystal polymorphism, and a crystal of compound A having a
particular crystal form is useful as a stable crystal, and based on
which findings, they have completed the present invention.
[0008] Accordingly, one or more embodiments of the present
invention provide the following. [0009] [1] A crystal (crystal form
II) of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which has an
X-ray powder diffraction pattern having characteristic diffraction
peaks at diffraction angles 2.theta.(.degree.) of 6.56, 13.20,
19.86, 20.84, 21.22, 25.22.degree. as measured by X-ray powder
diffractometer; [0010] [2] a crystal (crystal form III) of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which has an
X-ray powder diffraction pattern having characteristic diffraction
peaks at diffraction angles 2.theta.(.degree.) of 8.54, 14.02,
15.68, 17.06, 17.24, 24.16, 25.74.degree. as measured by X-ray
powder diffractometer; [0011] [3] a crystal (crystal form III) of
6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth-
oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an
extrapolated onset temperature of 162.1.+-.5.0.degree. C.; [0012]
[4] the crystal of any of the above-mentioned [1] to [3], which has
a purity of crystal of not less than 70%; [0013] [5] a mixed
crystal comprising the crystal of the above-mentioned 1 and the
crystal of the above-mentioned [2] or [3]; [0014] [6] the mixed
crystal of the above-mentioned [5], wherein the purity of crystal
is not less than 70%; [0015] [7] a pharmaceutical composition
comprising the crystal of any of the above-mentioned [1] to [4] or
the mixed crystal of the above-mentioned [5] or [6], and a
pharmaceutically acceptable carrier; [0016] [8] an integrase
inhibitor comprising the crystal of any of the above-mentioned [1]
to [4] or the mixed crystal of the above-mentioned [5] or [6] as an
active ingredient; [0017] [9] an antivirus agent comprising the
crystal of any of the above-mentioned [1] to [4] or the mixed
crystal of the above-mentioned [5] or [6] as an active ingredient;
[0018] [10] an anti-HIV agent comprising the crystal of any of the
above-mentioned [1] to [4] or the mixed crystal of the
above-mentioned [5] or [6] as an active ingredient; [0019] [11] an
anti-HIV composition comprising the crystal of any of the
above-mentioned [1] to [4] or the mixed crystal of the
above-mentioned [5] or [6] and one or more kinds of other anti-HIV
active substances as active ingredients; and [0020] [12] an
anti-HIV agent for a multiple drug therapy with other anti-HIV
agent, which comprises the crystal of any of the above-mentioned
[1] to [4] or the mixed crystal of the above-mentioned [5] or [6]
as an active ingredient.
[0021] The crystal or mixed crystal of compound A of the present
invention has the above-mentioned particular crystal form and is
superior in physical and chemical stability, which in turn has
advantage that maintenance of the quality of compound A for a
long-term becomes possible, which facilitates preservation. In
addition, they have advantage that handling during production of
various pharmaceutical compositions and bulk is easy, which reduces
the production cost.
DETAILED DESCRIPTION OF THE INVENTION
[0022] The present invention is explained in detail in the
following.
[0023] The term "crystal form II" of compound A means a crystal of
compound A, which has an X-ray powder diffraction pattern having
characteristic diffraction peaks at diffraction angles
2.theta.(.degree.) of 6.56, 13.20, 19.86, 20.84, 21.22,
25.22.degree. as measured by X-ray powder diffractometer.
[0024] The term "crystal form III" of compound A means a crystal of
compound A, which has an X-ray powder diffraction pattern having
characteristic diffraction peaks at diffraction angles
2.theta.(.degree.) of 8.54, 14.02, 15.68, 17.06, 17.24, 24.16,
25.74.degree. as measured by X-ray powder diffractometer.
[0025] The diffraction peak value at the above-mentioned
diffraction angle 2.theta.(.degree.) may show slight measurement
error due to the measurement instruments or measurement conditions
and the like. To be specific, the measurement error may be within
the range of about .+-.0.2, preferably about .+-.0.1, more
preferably about .+-.0.06.
[0026] In an embodiment, crystal of compound A of the present
invention is also characterized by thermal analysis. For example,
when the crystal form III of compound A of the present invention is
subjected to Differential Scanning Calorimetry (DSC), the enthalpy
of endothermic peak is about 81 J/g, and extrapolated onset
temperature is 162.1.+-.5.0.degree. C., preferably
162.1.+-.3.0.degree. C., more preferably 162.1.+-.1.0.degree. C.,
wherein the "extrapolated onset temperature" means, as defined by
JIS K 7121 (measurement method of transfer temperature of plastic),
the temperature at an intersection of the extrapolated baseline of
the lower temperature side toward the higher temperature side with
the tangent line drawn at the point showing the greatest slope on
the leading edge of the melting peak on a lower temperature side in
a DSC curve. When the enthalpy and extrapolated onset temperature
of the endothermic peak is within the above-mentioned range, the
crystal of compound A is stable.
[0027] In an embodiment, the crystal of compound A of the present
invention may be either a crystal form II or a crystal form III, or
a mixed crystal of a crystal form II and a crystal form III. For
use in a pharmaceutical product of compound A and the like, the
crystal form II or crystal form III is preferable because they are
stable crystals, and a crystal form III is more preferable because
it is the most stable crystal. In addition, a crystal form II is
preferable in view of the absorbability by living organisms upon
administration as a pharmaceutical composition.
[0028] The term "purity of crystal" means the purity of the crystal
form II or crystal form III of compound A. In the case of a mixed
crystal of a crystal form II and a crystal form III, it means the
ratio of crystal relative to the total amount of substance of a
crystal form II and a crystal form III. The purity of the crystal
of the present invention can be determined by, for example, known
methods such as X-ray powder diffractometry, thermal analysis, and
the like. The purity of the crystal or mixed crystal of the present
invention does not need to be 100%, and may be not less than 70%,
preferably not less than 80%, more preferably not less than 90%,
more preferably not less than 95%, more preferably not less than
98% Purity within this range is preferable for guaranteeing the
quality.
[0029] The crystal or mixed crystal of compound A of the present
invention can be administered to a mammal (human, mouse, rat,
hamster, rabbit, cat, dog, bovine, sheep, monkey, and the like.),
and the like as various pharmaceutical compositions such as
anti-HIV agents, HIV integrase inhibitors, antivirus agents, and
the like used for, for example, the prophylaxis and/or treatment of
AIDS.
[0030] When the crystal or mixed crystal of compound A of the
present invention is used as a pharmaceutical composition, it is
admixed with pharmaceutically acceptable carriers, excipients,
diluents, extending agents, disintegrants, stabilizers,
preservatives, buffers, emulsifiers, flavoring agents, coloring
agents, sweetening agents, thickeners, correctives, dissolution
aids, and other additives, that are generally known, such as water,
vegetable oil, alcohol (e.g., ethanol or benzyl alcohol, or the
like.), polyethylene glycol, glycerol triacetate, gelatin,
carbohydrate (e.g., lactose, starch, and the like.), magnesium
stearate, talc, lanolin, petrolatum, and the like, formed into
tablet, pill, powder, granule, suppository, injection, eye drop,
liquid, capsule, troche, aerosol, elixir, suspension, emulsion,
syrup, and the like by a conventional method, and administered
systemically or topically, and orally or parenterally.
[0031] While the dose varies depending on age, body weight,
symptom, treatment effect, administration method, and the like, it
is generally from about 0.01 mg to about 1 g per administration for
an adult, which is given once to several times a day orally or in a
dosage form of an injection such as intravenous injection and the
like.
[0032] An anti-HIV agent is generally required to sustain its
effect for a long time, so that it can be effective not only for
temporal suppression of viral growth but also for the prohibition
of viral re-growth. This means that a prolonged administration is
necessary and that a high single dose may be frequently inevitable
to sustain the effect for a longer period during night and the
like. Such prolonged and high dose administration increases the
risk of side effects.
[0033] In view of this, one of the preferable modes of the present
invention is such compound permitting high absorption by oral
administration, and such compound capable of maintaining blood
concentration of the administered compound for an extended period
of time.
[0034] By the "prophylaxis of AIDS" is meant, for example,
administration of a pharmaceutical agent to an individual who
tested HIV positive but has not yet developed the disease state of
AIDS, administration of a pharmaceutical agent to an individual who
shows an improved disease state of AIDS after treatment but who
carries HIV still to be eradicated and whose relapse of AIDS is
worried, and administration of a pharmaceutical agent out of a fear
of possible infection.
[0035] The anti-HIV composition of the present invention is used
for, for example, a multiple drug combination therapy of AIDS.
Examples of the "other anti-HIV active substance" to be used for
the anti-HIV composition include an anti-HIV antibody, an HIV
vaccine, immunostimulants such as interferon, and the like, an HIV
ribozyme, an HIV antisense drug, an HIV reverse transcriptase
inhibitor, an HIV protease inhibitor, an inhibitor of bond between
a bond receptor (CD4, CXCR4, CCR5, and the like) of a host cell
recognized by virus and the virus, and the like.
[0036] Specific examples of the HIV reverse transcriptase inhibitor
include Retrovir.RTM. (zidovudine), Epivir.RTM. (lamivudine),
Zerit.RTM. (sanilvudine), Videx.RTM. (didanosine), Hivid.RTM.
(zalcitabine), Ziagen.RTM. (abacavir sulfate), Viramune.RTM.
(nevirapine), Stocrin.RTM. (efavirenz), Rescriptor.RTM.
(delavirdine mesylate), Combivir.RTM. (zidovudine+lamivudine),
Trizivir.RTM. (abacavir sulfate+lamivudine+zidovudine),
Coactinon.RTM. (emivirine), Phosphonovir.RTM., Coviracil.RTM.,
alovudine (3'-fluoro-3'-deoxythymidine), Thiovir
(thiophosphonoformic acid), Capravirin
(5-[(3,5-dichlorophenyl)thio]-4-isopropyl-1-(4-pyridylmethyl)imidazole-2--
methanol carbamic acid), Tenofovir disoproxil fumarate
((R)-[[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic
acid bis(isopropoxycarbonyloxymethyl)ester fumarate), DPC-083
((4S)-6-chloro-4-[(1E)-cyclopropylethenyl]-3,4-dihydro-4-trifluoromethyl--
2(1H)-quinazolinone), DPC-961
((4S)-6-chloro-4-(cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-2(1-
H)-quinazolinone), DAPD ((-)-.beta.-D-2,6-diaminopurine dioxolane),
Immunocal, MSK-055, MSA-254, MSH-143, NV-01, TMC-120, DPC-817,
GS-7340, TMC-125, SPD-754, D-A4FC, capravirine, UC-781,
emtricitabine, alovudine, Phosphazid, UC-781, BCH-10618, DPC-083,
Etravirine, BCH-13520, MIV-210, Abacavir sulfate/lamivudine,
GS-7340, GW-5634, GW-695634, and the like, wherein (R) means a
registered trademark (hereinafter the same) and the names of other
pharmaceutical agents are general names.
[0037] Specific examples of the HIV protease inhibitor include
Crixivan.RTM. (indinavir sulfate ethanolate), saquinavir,
Invirase.RTM. (saquinavir mesylate), Norvir.RTM. (ritonavir),
Viracept.RTM. (nelfinavir mesylate), lopinavir, Prozei.RTM.
(amprenavir), Kaletra.RTM. (ritonavir+lopinavir), mozenavir
dimesylate ([4R-(4.alpha.,5.alpha.,6.beta.)]-1,3-bis
[(3-aminophenyl)methyl]-hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H--
1,3-diazepin-2-one dimethanesulfonate), tipranavir
(3'-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenylethyl-6-propyl-2H-p-
yran-3-yl]propyl]-5-(trifluoromethyl)-2-pyridinesulfonamide),
lasinavir
(N-[5(S)-(tert-butoxycarbonylamino)-4(S)-hydroxy-6-phenyl-2(R)-(2,3,4-tri-
methoxybenzyl)hexanoyl]-L-valine 2-methoxyethylenamide), KNI-272
((R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N-(isoquinolin-5-yloxya-
cetyl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-5,5-dimethyl-1,3-
-thiazolidine-4-carboxamide), GW-433908, TMC-126, DPC-681,
buckminsterfullerene, MK-944A (MK944
(N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-[4-(2-ben-
zo[b]furanylmethyl)-2(S)-(tert-butylcarbamoyl)piperazin-1-yl]pentanamide)+-
indinavir sulfate), JE-2147
([2(S)-oxo-4-phenylmethyl-3(S)-[(2-methyl-3-oxy)phenylcarbonylamino]-1-ox-
abutyl]-4-[(2-methylphenyl)methylamino]carbonyl-4(R)-5,5-dimethyl-1,3-thia-
zole), BMS-232632
((3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(pheny-
lmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecane-
dicarboxylic acid dimethyl ester), DMP-850
((4R,5S,6S,7R)-1-(3-amino-1H-indazol-5-ylmethyl)-4,7-dibenzyl-3-butyl-5,6-
-dihydroxyperhydro-1,3-diazepin-2-one), DMP-851, RO-0334649,
Nar-DG-35, R-944, VX-385, TMC-114, Tipranavir, Fosamprenavir
sodium, Fosamprenavir calcium, Darunavir, GW-0385, R-944,
RO-033-4649, AG-1859, and the like.
[0038] The HIV integrase inhibitor is exemplified by S-1360,
L-870810, and the like, the DNA polymerase inhibitor or DNA
synthesis inhibitor is exemplified by Foscavir(R), ACH-126443
(L-2',3'-didehydro-dideoxy-5-fluorocytidine), entecavir
((1S,3S,4S)-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine-
), calanolide A
([10R-(10.alpha.,11.beta.,12.alpha.)]-11,12-dihydro-12-hydroxy-6,6,10,11--
tetramethyl-4-propyl-2H,6H,10H-benzo[1,2-b:3,4-b':5,6-b'']tripyran-2-one),
calanolide B, NSC-674447 (1,1'-azobisformamide), Iscador (viscum
alubm extract), Rubitecan, and the like, the HIV antisense drug is
exemplified by HGTV-43, GEM-92, and the like, the anti-HIV antibody
or other antibody is exemplified by NM-01, PRO-367, KD-247,
Cytolin.RTM., TNX-355 (CD4 antibody), AGT-1, PRO-140 (CCR5
antibody), Anti-CTLA-4Mab, and the like, the HIV vaccine or other
vaccine is exemplified by ALVAC.RTM., AIDSVAX.RTM., Remune.RTM.,
HIVgp41 vaccine, HIVgp120 vaccine, HIVgp140 vaccine, HIVgp160
vaccine, HIVp17 vaccine, HIVp24 vaccine, HIVp55 vaccine, AlphaVax
Vector System, canarypox gp160 vaccine, AntiTat, MVA-F6 Nef
vaccine, HlVrev vaccine, C4-V3 peptide, p2249f, VIR-201, HGP-30W,
TBC-3B, PARTICLE-3B, and the like, Antiferon (interferon-.alpha.
vaccine), and the like, the interferon or interferon agonist is
exemplified by Sumiferon.RTM., MultiFeron.RTM., interferon-.tau.,
Reticulose, human leukocyte interferon .alpha., and the like, the
CCR5 antagonist is exemplified by SCH-351125 and the like, the
pharmaceutical agent acting on HIV p24 is exemplified by GPG-NH2
(glycyl-prolyl-glycinamide) and the like, the HIV fusion inhibitor
is exemplified by FP-21399
(1,4-bis[3-[(2,4-dichlorophenyl)carbonylamino]-2-oxo-5,8-disodium
sulfonyl]naphthyl-2,5-dimethoxyphenyl-1,4-dihydrazone), T-1249,
Synthetic Polymeric Construction No3, pentafuside, FP-21399,
PRO-542, Enfuvirtide, and the like, the IL-2 agonist or antagonist
is exemplified by interleukin-2, Imunace.RTM., Proleukin.RTM.,
Multikine.RTM., Ontak.RTM., and the like, the TNF-.alpha.
antagonist is exemplified by Thalomid.RTM. (thalidomide), is
Remicade.RTM. (infliximab), curdlan sulfate, the
.alpha.-glucosidase inhibitor is exemplified by Bucast.RTM. and the
like, the purine nucleoside phosphorylase inhibitor is exemplified
by peldesine
(2-amino-4-oxo-3H,5H-7-[(3-pyridyl)methyl]pyrrolo[3,2-d]pyrimidine)
and the like, the apoptosis agonist or inhibitor is exemplified by
Arkin Z.RTM., Panavir.RTM., Coenzyme Q10
(2-deca(3-methyl-2-butenylene)-5,6-dimethoxy-3-methyl-p-benzoquinone),
and the like, the cholinesterase inhibitor is exemplified by
Cognex.RTM. and the like, and the immunomodulator is exemplified by
Imunox.RTM., Prokine.RTM., Met-enkephalin
(6-de-L-arginine-7-de-L-arginine-8-de-L-valinamide-adrenorphin),
WF-10 (10-fold dilute tetrachlorodecaoxide solution), Perthon,
PRO-542, SCH-D, UK-427857, AMD-070, AK-602, and the like.
[0039] In addition, Neurotropin.RTM., Lidakol.RTM., Ancer 20.RTM.,
Ampligen.RTM., Anticort.RTM., Inactivin.RTM., and the like,
PRO-2000, Rev M10 gene, HIV specific cytotoxic T cell (CTL
immunotherapy, ACTG protocol 080 therapy, CD4-.zeta. gene therapy),
SCA binding protein, RBC-CD4 complex, Motexafin gadolinium, GEM-92,
CNI-1493, (.+-.)-FTC, Ushercell, D2S, BufferGel.RTM., VivaGel.RTM.,
Glyminox vaginal gel, sodium lauryl sulfate, 2F5, 2F5/2G12,
VRX-496, Ad5gag2, BG-777, IGIV-C, BILR-255, and the like are
exemplified.
[0040] As the "other anti-HIV activity substance" to be used for
the anti-HIV composition of the present invention in the multiple
drug combination therapy, preferred are an HIV reverse
transcriptase inhibitor and an HIV protease inhibitor. Two or
three, or even a greater number of pharmaceutical agents can be
used in combination, wherein a combination of pharmaceutical agents
having different action mechanisms is one of the preferable
embodiments. In addition, selection of pharmaceutical agents free
of side effect duplication is preferable.
[0041] Specific examples of the combination of pharmaceutical
agents include a combination of a group consisting of efavirenz,
tenofovir, emtricitabine, indinavir, nelfinavir, atazanavir,
ritonavir+indinavir, ritonavir+lopinavir and ritonavir+saquinavir,
didanosine+lamivudine, zidovudine+didanosine, stavudine+didanosine,
zidovudine+lamivudine, stavudine+lamivudine and emtriva, and the
crystal or mixed crystal of the present invention (Guidelines for
the Use of Antiretroviral Agents in HIV-Infected Adults and
Adolescents. Aug. 13, 2001). Particularly preferred is a combined
use of two agents of the crystal or mixed crystal of the present
invention with efavirenz, indinavir, nelfinavir, tenofovir,
emtricitabine, zidovudine or lamivudine, and a combined use of
three agents of the crystal or mixed crystal of the present
invention with zidovudine+lamivudine, tenofovir+lamivudine,
tenofovir+zidovudine, tenofovir+efavirenz, tenofovir+nelfinavir,
tenofovir+indinavir, tenofovir+emtricitabine,
emtricitabine+lamivudine, emtricitabine+zidovudine,
emtricitabine+efavirenz, emtricitabine+nelfinavir,
emtricitabine+indinavir, nelfinavir+lamivudine,
nelfinavir+zidovudine, nelfinavir+efavirenz, nelfinavir+indinavir,
efavirenz+lamivudine, efavirenz+zidovudine or
efavirenz+indinavir.
[0042] The production method of the crystal or mixed crystal of
compound A of the present invention is not particularly limited,
and the crystal can be produced by a method known or methods shown
in the following Examples, and the like.
EXAMPLES
[0043] While the production method of the crystal of compound A of
the present invention is explained in the following by referring to
Examples, which are mere examples and do not limit the present
invention in any way.
Reference Example 1
Production of Crystal Form I of the Compound A
[0044] Step 1
##STR00002##
[0045] 2,4-Difluorobenzoic acid (50 g, 316 mmol) was dissolved in
concentrated sulfuric acid (200 ml), and N-iodosuccinimide (68 g,
300 mmol) was added by portions at not more than 5.degree. C. After
the completion of the addition, the mixture was stirred at the same
temperature for 4.5 hr. The reaction mixture was poured into ice
water (ca. 600 ml), then 10% aqueous sodium sulfite solution was
added, and the mixture was stirred. The precipitated solid was
collected by filtration, washed with water, and vacuum dried to
give crude crystals (85 g). The crude crystals obtained in the same
manner were combined (total amount 205 g), and recrystallized from
50% aqueous ethanol (820 ml) to give 2,4-difluoro-5-iodobenzoic
acid (148 g, yield 73%) as a white solid.
[0046] .sup.1H NMR(CDCl.sub.3 300 MHz) (.sigma.) ppm: 6.94(1H, dd,
J=10.3, 10.3 Hz), 8.46 (1H, d, J=7.5 Hz)
[0047] Step 2
##STR00003##
[0048] The compound (148 g, 521 mmol) obtained in Step 1 was
dissolved in toluene (750 ml), thionyl chloride (76 ml, 1.04 mol)
and dimethylformamide (catalytic amount) were added, and the
mixture was heated under reflux for 2 hr. The insoluble material
was filtered off at 60.degree. C., and the filtrate was
concentrated under reduced pressure and azeotroped with toluene
(330 ml). The residue was dissolved in tetrahydrofuran (400 ml),
and this solution was added dropwise to a solution of ethyl
3,3-dimethylaminoacrylate (82 g, 573 mmol) and triethylamine (87
ml, 625 mmol) in tetrahydrofuran (400 ml), and the mixture was
heated under reflux for 7 hr. The reaction mixture was allowed to
cool to room temperature, and concentrated under reduced pressure.
Water (700 ml) and ethyl acetate (800 ml) were added for
partitioning. The organic layer was washed successively with
saturated aqueous sodium hydrogen carbonate (250 ml, .times.2),
water (300 ml) and saturated brine (300 ml), and dried over sodium
sulfate. After filtration of insoluble material, the filtrate was
concentrated under reduced pressure to give a crude product (210 g)
of 2-(2,4-difluoro-5-iodobenzoyl)-3-dimethylaminoacrylic acid ethyl
ester as a brown solid.
[0049] Step 3
##STR00004##
[0050] The crude product (210 g) obtained in Step 2 was dissolved
in tetrahydrofuran (500 ml), (S)-(+)-valinol (54 g, 521 mmol) was
added, and the mixture was stirred at room temperature for 30 min.
The reaction mixture was concentrated under reduced pressure, and
the residue was dissolved in dimethylformamide (600 ml). Potassium
carbonate (144 g, 1.04 mol) was added and the mixture was stirred
with heating at 70.degree. C. for 2 hr. The reaction mixture was
allowed to cool, and added to water (1500 ml) and stirred. The
precipitated solid was collected by filtration and the obtained
solid was washed successively with 30% aqueous ethanol (500 ml) and
a mixed solvent of diethyl ether (150 ml) and hexane (150 ml) and
vacuum dried to give
7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropyl)-6-iodo-4-oxo-1,4-dihydroq-
uinoline-3-carboxylic acid ethyl ester (178 g, yield 76%) as a
beige solid.
[0051] .sup.1H NMR(DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72(3H, d,
J=6.6 Hz), 1.10 (3H, d, J=6.6 Hz), 1.28(3H, t, J=7.0 Hz), 2.27 (1H,
br), 3.77 (1H, br), 3.86(1H, br), 4.23 (2H, q, J=7.0 Hz), 4.56(1H,
br), 5.12 (1H, t, J=4.9 Hz), 8.09(1H, d, J=11.1 Hz), 8.62 (1H, d,
J=7.5 Hz), 8.68(1H, s)
[0052] MS(ESI): M+ 448
[0053] Step 4
##STR00005##
[0054] wherein TBDMS means a tert-butyldimethylsilyl group.
[0055] The compound (80 g, 179 mmol) obtained in Step 3 was
dissolved in dimethylformamide (320 ml), imidazole (16 g, 233 mmol)
and tert-butyldimethylsilyl chloride (30 g, 197 mmol) were added,
and the mixture was stirred at room temperature for 1.5 hr. Water
was added to the reaction mixture and the mixture was extracted
with ethyl acetate. The organic layer was washed successively with
saturated aqueous ammonium chloride solution and saturated brine,
and dried over sodium sulfate. The organic layer was filtered and
the filtrate was concentrated under reduced pressure. The obtained
residue was purified by silica gel chromatography (ethyl
acetate:hexane=1:3 to 1:2) to give
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-7-fluoro-6-iodo-
-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester (77 g,
yield 77%) as a colorless amorphous form.
[0056] .sup.1H NMR(CDCl.sub.3 400 MHz) (.delta.) ppm: -0.07(3H, s),
-0.05(3H, s), 0.77(9H, s), 0.84(3H,d, J=6.5 Hz), 1.18(3H, d, J=6.5
Hz), 1.40(3H, t, J=7.2 Hz), 2.35-2.50(1H, m), 3.85-3.95(1H, m),
3.98-4.10(2H, m), 4.30-4.40(2H, m), 7.26(1H,s), 8.64(1H, s),
8.94(1H, d, J=7.2Hz)
[0057] MS(ESI): M+ 562
[0058] Step 5
##STR00006##
[0059] (Preparation of a solution of 3-chloro-2-fluorobenzylzinc
bromide in tetrahydrofuran)
[0060] Under an argon stream, zinc powder (11 g, 267 mmol) was
suspended in tetrahydrofuran (30 ml), 1,2-dibromoethane (0.15 ml,
1.8 mmol) and trimethylsilyl chloride (0.45 ml, 3.6 mmol) were
added at 65.degree. C., and the mixture was stirred with heating
for 30 min. A solution of 3-chloro-2-fluorobenzyl bromide (41 g,
178 mmol) in tetrahydrofuran (100 ml) was added dropwise at
65.degree. C., and the mixture was stirred with heating for 2 hr
and allowed to cool to room temperature to give a solution of 1M
3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran. This was
used in the next main step.
[0061] Main Step
[0062] The compound (76 g, 136 mmol) obtained in Step 4 was
dissolved in tetrahydrofuran (600 ml) and, under an argon stream,
dibenzylidenacetonepalladium(II) (3.2 g, 5.5 mmol) and
trifurylphosphine (2.6 g, 11.0 mmol) were added, and a solution of
the aforementioned 1M 3-chloro-2-fluorobenzylzinc bromide in
tetrahydrofuran (178 ml, 178 mmol) was added dropwise at 60.degree.
C. After the completion of the dropwise addition, the mixture was
stirred with heating at the same temperature for 2 hr. The reaction
mixture was allowed to cool to room temperature, saturated aqueous
ammonium chloride solution was added, and the mixture was filtered
through celite. The filtrate was extracted twice with ethyl
acetate. The organic layer was washed successively with water
(twice) and saturated brine, and dried over magnesium sulfate. The
organic layer was filtered and the filtrate was concentrated under
reduced pressure, and the obtained residue was purified by silica
gel chromatography (chloroform:acetone=40:1) to give
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chloro-2-f-
luorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ethyl ester (68 g, yield 84%) as a colorless amorphous form.
[0063] .sup.1H NMR(CDCl.sub.3 400 MHz) (.delta.) ppm: -0.09(3H, s),
-0.05(3H, s), 0.75(9H, s), 0.85(3H,d, J=6.7 Hz), 1.18(3H, d, 6.7
Hz), 1.39(3H, t, J=7.1 Hz), 2.45(1H, br), 3.89-3.92(1H, m),
3.98-4.02(1H, m), 4.07-4.12(1H, m), 4.12(2H, s), 4.34-4.41(2H, m),
6.96-7.00(1H, m), 7.03-7.05(1H, m), 7.21-7.24(1H, m), 7.26-7.29(1H,
m), 8.39(1H, d, J=8.8 Hz), 8.63(1H, s)
[0064] Step 6
##STR00007##
[0065] The compound (48 g, 86 mmol) obtained in Step 5 was
dissolved in methanol (300 ml), water (5 ml) and 28% sodium
methoxide methanol solution (176 ml, 862 mmol) were added, and the
mixture was heated under reflux for 24 hr. The reaction mixture was
allowed to cool to room temperature and the mixture was neutralized
by adding 6N hydrochloric acid. Methanol was evaporated under
reduced pressure. Water was added to the obtained solution and the
mixture was stirred. The precipitated solid was collected by
filtration and the obtained solid was dissolved in ethyl acetate.
The mixture was washed with water and dried over sodium sulfate.
The solution was filtered and the filtrate was concentrated under
reduced pressure. The obtained residue was recrystallized from
ethyl acetate-hexane to give a compound (32 g, yield 86%) as a
white solid. The obtained compound (32 g) was dissolved in butyl
acetate (160 ml) by heating under reflux, and crystal form II was
seeded at 75.degree. C. The mixture was stirred for 3.5 hr while
allowing to cool as it was. The precipitated solid was collected by
filtration, washed with butyl acetate (25 ml) and vacuum dried to
give a compound (25 g, yield 77%) as a white solid. The obtained
compound (4.0 g) was dissolved in methanol (40 ml) by heating under
reflux at 50.degree. C., and added dropwise to water (40 ml) at
room temperature. The mixture was stirred at room temperature for
16 hr, filtered, and the remaining solid was washed with 66%
aqueous methanol, and vacuum dried to give a crystal of compound A
(crystal form I) (3.9 g, yield 97%) as a white solid.
[0066] m.p. 151-152.degree. C.
[0067] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72 (3H,
d, J=6.5 Hz), 1.16 (3H, d, J=6.5 Hz), 2.30-2.50 (1H, m), 3.70-3.90
(1H, m), 3.90-4.00 (1H, m), 4.03 (3H, s), 4.12 (2H,s), 4.80-4.90
(1H, m), 5.19 (1H, t), 7.19-7.25 (2H, m), 7.46-7.51 (2H, m),
8.04(1H, s), 8.88 (1H, s), 15.44 (1H, s)
[0068] MS (ESI) : M+ 448
Example 1
Production of Crystal Form II of the Compound A
[0069] Step 1
##STR00008##
[0070] 2,4-Difluorobenzoic acid (50 g, 0.316 mmol) was dissolved in
concentrated sulfuric acid (200 ml), and N-iodosuccinimide (68 g,
300 mmol) was added by portions at not more than 5.degree. C. After
the completion of the addition, the mixture was stirred at the same
temperature for 4.5 hr. The reaction mixture was poured into ice
water (ca. 600 ml), then 10% aqueous sodium sulfite solution was
added, and the mixture was stirred. The precipitated solid was
collected by filtration, washed with water, and vacuum dried to
give crude crystals (85 g). The crude crystals obtained in the same
manner were combined (total amount 205 g), and recrystallized from
50% aqueous ethanol (820 ml) to give 2,4-difluoro-5-iodobenzoic
acid (148 g, yield 73%) as a white solid.
[0071] .sup.1H NMR(CDCl.sub.3 300 MHz) (.sigma.) ppm: 6.94(1H, dd,
J=10.3, 10.3 Hz), 8.46 (1H, d, J=7.5 Hz)
[0072] Step 2
##STR00009##
[0073] The compound (148 g, 521 mmol) obtained in Step 1 was
dissolved in toluene (750 ml), thionyl chloride (76 ml, 1.04 mol)
and dimethylformamide (catalytic amount) were added, and the
mixture was heated under reflux for 2 hr. The insoluble material
was filtered off at 60.degree. C., and the filtrate was
concentrated under reduced pressure and azeoptoped with toluene
(330 ml). The residue was dissolved in tetrahydrofuran (400 ml),
and this solution was added dropwise to a solution of ethyl
3,3-dimethylaminoacrylate (82 g, 573 mmol) and triethylamine (87
ml, 625 mmol) in tetrahydrofuran (400 ml), and the mixture was
heated under reflux for 7 hr. The reaction mixture was allowed to
cool to room temperature and concentrated under reduced pressure.
Water (700 ml) and ethyl acetate (800 ml) were added to allow
partitioning. The organic layer was washed successively with
saturated aqueous sodium hydrogen carbonate (250 ml) twice, water
(300 ml) and saturated brine (300 ml), and dried over sodium
sulfate. The mixture was filtered, and the filtrate was
concentrated under reduced pressure to give a crude product (210 g)
of 2-(2,4-difluoro-5-iodobenzoyl)-3-dimethylaminoacrylic acid ethyl
ester as a brown solid.
[0074] Step 3
##STR00010##
[0075] The crude product (210 g) obtained in Step 2 was dissolved
in tetrahydrofuran (500 ml), (S)-(+)-valinol (54 g, 0.521 mmol) was
added, and the mixture was stirred at room temperature for 30 min.
The reaction mixture was concentrated under reduced pressure, and
the residue was dissolved in dimethylformamide (600 ml). Potassium
carbonate (144 g, 1.04 mol) was added, and the mixture was stirred
with heating at 70.degree. C. for 2 hr. The reaction mixture was
allowed to cool to room temperature, added to water (1500 ml) and
the mixture was stirred. The precipitated solid was collected by
filtration. The obtained solid was washed successively with 30%
aqueous ethanol (500 ml) and a mixed solvent of diethyl ether (150
ml) and hexane (150 ml), and vacuum dried to give
7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropyl)-6-iodo-4-oxo-1,4-dihydroq-
uinoline-3-carboxylic acid ethyl ester (178 g, yield 76% (relative
to Step 2)) as a beige solid.
[0076] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72(3H,
d, J=6.6 Hz), 1.10 (3H, d, J=6.6 Hz), 1.28(3H, t, J=7.0 Hz), 2.27
(1H, br), 3.77 (1H, br), 3.86(1H, br), 4.23 (2H, q, J=7.0 Hz),
4.56(1H, br), 5.12 (1H, t, J=4.9 Hz), 8.09(1H, d, J=11.1 Hz), 8.62
(1H, d, J=7.5Hz), 8.68(1H, s)
[0077] MS(ESI): M+ 448
[0078] Step 4
##STR00011##
[0079] The compound (150 g, 335 mmol) obtained in Step 3 was
dissolved in dimethylformamide (500 ml), imidazole (30 g, 0.436
mmol) and tert-butyldimethylsilyl chloride (56 g, 369 mmol) were
added, and the mixture was stirred at room temperature for 1.5 hr.
Water was added to the reaction mixture and extracted with ethyl
acetate. The organic layer was washed successively with water,
saturated aqueous ammonium chloride solution and saturated brine,
and dried over sodium sulfate. The organic layer was filtered and
the filtrate was concentrated under reduced pressure, and the
obtained residue was purified by silica gel chromatography (ethyl
acetate:hexane=1:3 to 1:2) to give
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-7-fluoro-6-iodo-
-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester (173 g,
yield 92%) as a colorless amorphous form.
[0080] .sup.1H NMR(CDCl.sub.3 400 MHz) (.delta.) ppm: -0.07(3H, s),
-0.05(3H, s), 0.77(9H, s), 0.84(3H,d, J=6.5 Hz), 1.18(3H, d, J=6.5
Hz), 1.40(3H, t, J=7.2 Hz), 2.35-2.50(1H, m), 3.85-3.95(1H, m),
3.98-4.10(2H, m), 4.30-4.40(2H, m), 7.26(1H,s), 8.64(1H, s),
8.94(1H, d, J=7.2 Hz)
[0081] MS(ESI): M+ 562
[0082] Step 5
##STR00012##
[0083] (Preparation of a solution of 3-chloro-2-fluorobenzylzinc
bromide in tetrahydrofuran)
[0084] Under an argon stream, zinc powder (11 g, 175 mmol) was
suspended in tetrahydrofuran (30 ml), 1,2-dibromoethane (0.1 ml,
1.20 mmol) and trimethylsilyl chloride (0.29 ml, 2.4 mmol) were
added at 60.degree. C., and the mixture was stirred with heating
for 30 min. A solution of 3-chloro-2-fluorobenzyl bromide (27 g,
119 mmol) in tetrahydrofuran (60 ml) was added dropwise at
60.degree. C. The mixture was stirred with heating for 1 hr and
allowed to cool to room temperature to give a solution of 1M
3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran. This was
used in the next main step.
[0085] Main Step
[0086] The compound (50 g, 89 mmol) obtained in Step 4 was
dissolved in tetrahydrofuran (400 ml) and, under an argon stream,
dichlorobis(triphenylphosphine)palladium(II) (2.1 g, 3.6 mmol) was
added and a solution of the above-mentioned 1M
3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran was added
dropwise at 60.degree. C. After the completion of the dropwise
addition, the mixture was stirred with heating at the same
temperature for 1.5 hr. The reaction mixture was allowed to cool to
room temperature, 1N hydrochloric acid was added and the mixture
was extracted 3 times with ethyl acetate. The organic layer was
washed successively with water and saturated brine, and dried over
magnesium sulfate. The organic layer was filtered and the filtrate
was concentrated under reduced pressure, and the obtained residue
was purified by silica gel chromatography (ethyl acetate:hexane=1:2
to 1:1) to give
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chloro-2-f-
luorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ethyl ester (43 g, yield 83%) as a brown amorphous form.
[0087] .sup.1H NMR(CDCl.sub.3 400 MHz) (.delta.) ppm: -0.09(3H, s),
-0.05(3H, s), 0.75(9H, s), 0.85(3H,d, J=6.7 Hz), 1.18(3H, d,
6.7Hz), 1.39(3H, t, J=7.1 Hz), 2.45(1H, br), 3.89-3.92(1H, m),
3.98-4.02(1H, m), 4.07-4.12(1H, m), 4.12(2H, s), 4.34-4.41(2H, m),
6.96-7.00(1H, m), 7.03-7.05(1H, m), 7.21-7.24(1H, m), 7.26-7.29(1H,
m), 8.39(1H, d, J=8.8Hz), 8.63(1H, s)
[0088] Step 6
##STR00013##
[0089] The compound (43 g, 74 mmol) obtained in Step 5 was
dissolved in methanol (280 ml), 28% sodium methoxide methanol
solution (151 ml, 742 mmol) and water (4.3 ml) were added, and the
mixture was heated under reflux for 20 hr. The reaction mixture was
filtered through celite. The filtrate was concentrated under
reduced pressure. Water (400 ml) was added to the residue, and the
mixture was washed with hexane (100 ml). The aqueous layer was
acidified by adding concentrated hydrochloric acid (65 ml), and the
mixture was extracted with ethyl acetate. The organic layer was
washed successively with water and saturated brine, and dried over
sodium sulfate. The solution was filtered and the filtrate was
concentrated under reduced pressure. The obtained crude product (35
g, brown oil) was dissolved in ethyl acetate (49 ml) by heating
under reflux, hexane (30 ml) was added while allowing to cool, and
the mixture was stirred for 18.5 hr. The precipitated solid was
collected by filtration, washed with a mixed solvent of ethyl
acetate and hexane (1:1), and vacuum dried to give a crystal of
compound A (crystal form II) (27 g, yield 82%) as a white
solid.
[0090] m.p. 153.7-153.9.degree. C.
[0091] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72 (3H,
d, J=6.5Hz), 1.16 (3H, d, J=6.5 Hz), 2.30-2.50 (1H, m), 3.70-3.90
(1H, m), 3.90-4.00 (1H, m), 4.03 (3H, s), 4.12 (2H,s), 4.80-4.90
(1H, m), 5.19 (1H, t), 7.19-7.25 (2H, m), 7.46-7.51 (2H, m),
8.04(1H, s), 8.88 (1H, s), 15.44 (1H, s)
[0092] MS (ESI): M+ 448
Example 2
Production of Crystal Form II of the Compound A
Example 2-1
Production of Crystal Form II of the Compound A
[0093] Step 1
##STR00014##
[0094] 2,4-Difluorobenzoic acid (100 g, 633 mmol) was dissolved in
concentrated sulfuric acid (400 ml), and N-iodosuccinimide (142 g,
601 mol) was added by portions at not more than 5.degree. C. After
the completion of the addition, the mixture was stirred at the same
temperature for 6 hr. The reaction mixture was poured into ice
water (ca. 2400 ml), then saturated aqueous sodium sulfite solution
was added, and the mixture was stirred. The precipitated solid was
collected by filtration, washed with water, and vacuum dried to
give crude crystals (188 g). The crude crystals obtained in the
same manner were combined (total amount 568 g), and recrystallized
from 50% aqueous ethanol (2600 ml) to give
2,4-difluoro-5-iodobenzoic acid (388 g, yield 68%) as a white
solid.
[0095] .sup.1H NMR(CDCl.sub.3 300 MHz) (.sigma.) ppm: 6.94(1H, dd,
J=10.3, 10.3 Hz), 8.46 (1H, d, J=7.5 Hz)
[0096] Step 2
##STR00015##
[0097] The compound (200 g, 704 mmol) obtained in Step 1 was
dissolved in toluene (1000 ml), thionyl chloride (103 ml, 408 mmol)
and dimethylformamide (catalytic amount) were added, and the
mixture was heated under reflux for 2 hr. The insoluble material
was filtered off, and the filtrate was concentrated under reduced
pressure and azeotroped with toluene. The residue was dissolved in
tetrahydrofuran (500 ml), this solution was added dropwise to a
solution of ethyl 3,3-dimethylaminoacrylate (111 g, 775 mmol) and
triethylamine (118 ml, 845 mmol) in tetrahydrofuran (500 ml), and
the mixture was heated under reflux for 3 hr. The reaction mixture
was allowed to cool to room temperature and filtered and the
filtrate was concentrated under reduced pressure. Water (500 ml)
and ethyl acetate (800 ml) were added to allow partitioning. The
organic layer was washed successively with saturated aqueous sodium
hydrogen carbonate (200 ml), water (200 ml) and saturated brine,
and dried over sodium sulfate. The organic layer was filtered, and
the filtrate was concentrated under reduced pressure to give a
crude product (273 g) of
2-(2,4-difluoro-5-iodobenzoyl)-3-dimethylaminoacrylic acid ethyl
ester as a brown solid.
[0098] Step 3
##STR00016##
[0099] The crude product (273 g) obtained in Step 2 was dissolved
in tetrahydrofuran (650 ml), (S)-(+)-valinol (73 g, 708 mmol) was
added, and the mixture was stirred at room temperature for 2 hr.
The reaction mixture was concentrated under reduced pressure and
the residue was dissolved in dimethylformamide (800 ml). Potassium
carbonate (195 g 1.41 mol) was added, and the mixture was stirred
with heating at 70.degree. C. for 2.5 hr. The reaction mixture was
allowed to cool to room temperature, added to water (2000 ml) and
the mixture was stirred. The precipitated solid was collected by
filtration. The obtained solid was subject to slurry washing
successively with water and 30% aqueous ethanol (650 ml) and vacuum
dried to give a crude product (217 g). The obtained crude product
(217 g) was subject to slurry washing with a mixed solvent of ethyl
acetate (650 ml) and hexane (440 ml) with heating under reflux. The
mixture was filtered, and the remaining solid was vacuum dried to
give
7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropyl)-6-iodo-4-oxo-1,4-dihydroq-
uinoline-3-carboxylic acid ethyl ester (207 g, yield 66% (relative
to Step 2)) as a pale-brown solid.
[0100] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72(3H,
d, J=6.6 Hz), 1.10 (3H, d, J=6.6 Hz), 1.28(3H, t, J=7.0 Hz), 2.27
(1H, br), 3.77 (1H, br), 3.86(1H, br), 4.23 (2H, q, J=7.0 Hz),
4.56(1H, br), 5.12 (1H, t, J=4.9 Hz), 8.09(1H, d, J=11.1 Hz), 8.62
(1H, d, J=7.5 Hz), 8.68(1H, s)
[0101] MS(ESI): M+ 448
[0102] Step 4
##STR00017##
[0103] The compound (150 g, 335 mmol) obtained in Step 3 was
dissolved in dimethylformamide (450 ml), imidazole (27 g, 397 mmol)
and tert-butyldimethylsilyl chloride (58 g, 385 mmol) were added,
and the mixture was stirred overnight at room temperature. Water
(900 ml) was added to the reaction mixture, and the mixture was
extracted with ethyl acetate (680 ml). The organic layer was washed
successively with water (450 ml, 3 times) and saturated brine (200
ml), and dried over sodium sulfate. The organic layer was filtered,
and the filtrate was concentrated under reduced pressure to give a
crude product (192 g) of
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-7-fluoro-6-iodo-
-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester as a
pale-yellow amorphous form.
[0104] Step 5
##STR00018##
[0105] The crude product (162 g) obtained in Step 4 was dissolved
in tetrahydrofuran (160 ml) and, under an argon stream,
dibenzylidenacetone palladium(II) (1.7 g, 2.9 mmol) and
trifurylphosphine (1.3 g, 5.8 mmol) were added. To this mixture was
added dropwise at 60.degree. C. a solution of (375 ml, 375 mmol) of
1M 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran obtained
in the same manner as in Example 1, Step 5 and, after the
completion of the dropwise addition, the mixture was stirred with
heating at the same temperature far 3.5 hr. The reaction is mixture
was allowed to cool to room temperature, ethyl acetate (640 ml) and
10% aqueous citric acid solution (400 ml) were added, and the
mixture was filtered through Celite, and the filtrate was
partitioned. The organic layer was washed successively with water
(200 ml), saturated aqueous sodium hydrogen carbonate (400 ml) and
saturated brine (200 ml), and dried over sodium sulfate. The
organic layer was filtered, and the filtrate was concentrated under
reduced pressure to give a crude product (186 g) of
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chloro-2-f-
luorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ethyl ester as a brown oil.
[0106] Step 6
##STR00019##
[0107] The crude product (193 g) obtained in Step 5 was dissolved
in isopropanol (650 ml), 1N aqueous sodium hydroxide solution (1290
ml, 1.29 mol) was added, and the mixture was heated under reflux
for 2 hr. The reaction mixture was allowed to cool to room
temperature, and filtered through Celite. The filtrate was
acidified by adding concentrated hydrochloric acid and the mixture
was stirred. The precipitated solid was collected by filtration,
and vacuum dried to give a crude product (132 g) as a pale-yellow
solid. The crude products obtained in the same manner were combined
(total amount 143 g), suspended in butyl acetate (430 ml) and
subject to slurry stirring with heating under reflux for 1 hr. The
suspension was allowed to cool to room temperature and filtered and
vacuum dried to give
6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropy-
l)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (99 g, yield 74%
(relative to Step 3)) as a gray solid.
[0108] .sup.1H NMR (DMSO-d.sub.6 400 MHz) (.delta.) ppm: 0.71 (3H,
d, J=6.5Hz), 1.13 (3H, d, J=6.5 Hz), 2.36 (1H, br), 3.77(1H, br),
3.94 (1H, br), 4.25 (2H, s), 4.77(1H, br), 5.16 (1H,
[0109] t, J=2.4 Hz), 7.19-7.23(1H, m), 7.32-7.35 (1H, m), 7.48-7.52
(1H, m), 8.24-8.28 (2H, m), 9.00 (1H, s), 15.00 (1H, s)
[0110] MS(ESI): M+ 436
[0111] Step 7
##STR00020##
[0112] The compound (99 g, 227 mmmol) obtained in Step 6 was
dissolved in methanol (530 ml), 28% sodium methoxide methanol
solution (465 ml, 2.28 mol) was added, and the mixture was heated
under reflux for 20 hr. The reaction mixture was allowed to cool to
room temperature and filtered through Celite. The filtrate was
concentrated under reduced pressure. The residue was acidified by
adding water (200 ml) and concentrated hydrochloric acid (190 ml),
and extracted with ethyl acetate (500 ml). The organic layer was
washed twice with water (200 ml), and dried over sodium sulfate.
The mixture was filtered, and the filtrate was concentrated under
reduced pressure to give a crude product (108 g). The obtained
crude product (108 g) was dissolved in isobutyl acetate (330 ml)
with heating and the mixture was stirred while allowing to cool for
24 hr. The precipitated solid was collected by filtration, and
vacuum dried to give compound A (71 g, yield 69%) as a white solid.
The crude crystals obtained in the same manner were combined (total
amount 233 g), dissolved in isobutyl acetate (470 ml) by heating
under reflux, and the mixture was stirred overnight while allowing
to cool. The precipitated solid was collected by filtration, and
vacuum dried to give a crystal of compound A (crystal form II) (206
g, yield 88%) as a white solid.
[0113] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72 (3H,
d, J=6.5 Hz), 1.16 (3H, d, J=6.5 Hz), 2.30-2.50 (1H, m), 3.70-3.90
(1H, m), 3.90-4.00 (1H, m), 4.03 (3H, s), 4.12 (2H, s), 4.80-4.90
(1H, m), 5.19 (1H, t), 7.19-7.25 (2H, m), 7.46-7.51 (2H, m), 8.04
(1H, s), 8.88 (1H, s), 15.44 (1H, s)
[0114] MS (ESI): M+ 448
Example 2-2
Production of Crystal Form II of the Compound A
[0115] Step 1
##STR00021##
[0116] 5-Bromo-2,4-difluorobenzoic acid (82.7 kg, 349 mol) was
dissolved in toluene (420 L), thionyl chloride (62.3 kg, 523 mol)
and dimethylformamide (catalytic amount) were added, and the
mixture was stirred at 70.degree. C. for 6 hr. The reaction mixture
was allowed to cool to room temperature, concentrated under reduced
pressure, and azeotroped again with toluene (420 L). The residue
was dissolved in toluene (220 L), this solution was added dropwise
to a solution of ethyl 3,3-dimethylaminoacrylate (55.0 kg, 384 mol)
and diisopropylethylamine (58.6 kg, 523 mol) in toluene (220 L),
and the mixture was stirred with heating at 70.degree. C. for 21
hr. The reaction mixture was allowed to cool to room temperature,
(S)-(+)-valinol (36.0 kg, 349 mol) was added, and the mixture was
stirred at room temperature for 1.5 hr. Water (420 L) was added to
the reaction mixture to allow partitioning, and the organic layer
was washed successively with 1N hydrochloric acid (250 L, twice),
water (420 L), 5% aqueous sodium hydrogen carbonate (250 L, twice),
water (420 L) and 10% brine (250 L). The extract was concentrated
under reduced pressure and azeotroped with dimethylformamide (420
L) to give a concentration residue (330 L) containing a crude
product of
2-(5-bromo-2,4-difluorobenzoyl)-3-((S)-1-hydroxymethyl-2-methylpropylmeth-
ylamino)acrylic acid ethyl ester.
[0117] Step 2
##STR00022##
[0118] To a solution (330 L) of the crude product obtained in Step
1 in dimethylformamide was added 1,8-diazabicyclo[5.4.0]undecane
(105 kg, 349 mol) and the mixture was stirred at room temperature
for 23 hr. To the reaction mixture were added dimethylformamide
(330 L), and then water (170 L) and, after stirring for 2 hr, water
(170 L) was added dropwise. The precipitated solid was collected by
filtration and washed with dimethylformamide (170 L)-water (170 L)
mixture, and then with ethanol (460 L)-water (200 L) mixed
solution. The obtained solid was vacuum dried, suspended in an
ethyl acetate (330 L)-n-heptane (330 L) mixture and subject to
slurry washing. The suspension was filtered, and the remaining
solid was vacuum dried to give
6-bromo-7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropyl)-4-oxo-1,4-dihydro-
quinoline-3-carboxylic acid ethyl ester (102 kg, yield 73%) as a
yellow white solid. This compound was confirmed to be equivalent to
the standard product of the compound by high performance liquid
chromatography (HPLC) analysis.
[0119] Step 3
##STR00023##
[0120] The compound (45.0 kg, 112 mol) obtained in Step 2 and
imidazole (9.95 kg, 146 mol) were suspended in toluene (180 L), a
solution of tert-butyldimethylsilyl chloride (17.8 kg, 118 mol) in
toluene (45 L) was added at 50.degree. C., and the mixture was
stirred at the same temperature for 3 hr. Toluene (230 L) was added
to the reaction mixture, and washed successively with water (450 L,
twice) and 20% brine (450 L). The extract was concentrated under
reduced pressure and azeotroped with tetrahydrofuran (320 L) to
give a concentration residue (390 L) containing a crude product of
6-bromo-1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-7-fluor-
o-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester.
[0121] Step 4
##STR00024##
[0122] (Preparation of a solution of 3-chloro-2-fluorobenzylzinc
bromide in tetrahydrofuran)
[0123] Under a nitrogen stream, zinc powder (18.8 kg, 287 mol) was
suspended in tetrahydrofuran (130 L), 1,2-dibromoethane (470 g,
2.50 mol) was added at 60.degree. C., and the mixture was stirred
at the same temperature for 30 min. Trimethylsilyl chloride (560 g,
3.10 mol) was added to this suspension at room temperature, and the
mixture was stirred with heating for 30 min. A solution of
3-chloro-2-fluorobenzyl bromide (54.0 kg, 242 mol) in
tetrahydrofuran (65 L) was added dropwise at 0.degree. C., and the
mixture was stirred at 20.degree. C. for 3 hr. The remaining zinc
was filtered off to give a solution of 1M
3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran. This was
used in the next main step.
[0124] Main Step
[0125] Under a nitrogen stream,
tris(dibenzylidenacetone)dipalladium(0) (1.96 kg, 3.36 mol) and
triphenylphosphine (1.77 kg, 6.72 mol) were dissolved in
tetrahydrofuran (180 L), and the mixture was stirred at room
temperature for 1 hr. A solution (390 L) of the crude product
obtained in Step 3 in tetrahydrofuran was added dropwise at room
temperature and washed with tetrahydrofuran (45 L). A solution (164
kg, 157 mol) of the above-mentioned 1M 3-chloro-2-fluorobenzylzinc
bromide in tetrahydrofuran prepared in advance was added dropwise
at room temperature, and the mixture was stirred with heating at
55.degree. C. for 5 hr. The reaction mixture was allowed to cool to
room temperature, toluene (230 L) and 25% aqueous ammonium chloride
solution (230 L) were added and the mixture was stirred. After
filtration, the mixture was partitioned. The organic layer was
washed successively with 25% aqueous ammonium chloride solution
(230 L), water (230 L), 5% aqueous sodium hydrogen carbonate (230
L, 3 times) and 10% brine (230 L). The extract was concentrated
under reduced pressure to give a crude product (80 L) of
6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropy-
l)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as a brown oil.
[0126] Step 5
[0127] The crude product (80 L) obtained in Step 4 was dissolved in
isopropanol (180 L), 1N aqueous sodium hydroxide solution (160 L,
180 mol) was added, and the mixture was stirred with heating at
50.degree. C. for 9 hr. Activated carbon (4.5 kg) was added to the
reaction mixture. The mixture was stirred at room temperature for
30 min, filtered through cellulose powder and thoroughly washed
with an isopropanol (45 L)-water (45 L) mixture. Water (180 L) and
n-heptane (230 L) were added to the filtrate and, after stirring,
the mixture was partitioned. The aqueous layer was washed again
with n-heptane (230 L). 4N Hydrochloric acid (45 L, 180 mol) and
methyl isopropyl ketone (450 L) were added to the organic layer
and, after stirring, the mixture was partitioned. The organic layer
was washed successively with 10% brine (230 L), twice with 8.5%
aqueous sodium hydrogen carbonate (230 L), 0.5N hydrochloric acid
(230 L) and water (230 L). The extract was concentrated under
reduced pressure, azeotroped 3 times with toluene (230 L). The
residue was stirred at 100.degree. C. for 1.5 hr, allowed to cool
to room temperature and stirred for 3 hr. The precipitated solid
was collected by filtration and the obtained solid was washed with
toluene (45 L) and vacuum dried to give
6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[(S)-1-hydroxymethyl-2-methyl-
propyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (42.5 kg,
yield 87%) as a pale-yellow solid. This compound was confirmed to
be equivalent to the standard product by HPLC analysis.
[0128] Step 6
##STR00025##
[0129] The compound (39.2 kg, 89.9 mol) obtained in Step 5 was
dissolved in methanol (240 L), 28% sodium methoxide methanol
solution (173 kg, 899 mol) was added dropwise at 10.degree. C., and
the mixture was stirred with heating at 70.degree. C. for 21 hr.
Activated carbon (3.9 kg) was added to the reaction mixture. The
mixture was stirred at room temperature for 1 hr, filtered through
cellulose powder and thoroughly washed with methanol. (80 L). Water
(29 kg, 1620 mol) was added to the filtrate and the mixture was
concentrated under reduced pressure. The residue was azeotroped
twice with isopropanol (240 L, 120 L). To the residue were added
15% brine (200 L) and toluene (200 L) and, after stirring, the
mixture was partitioned. The organic layer was washed successively
with 20% brine (200 L, 3 times), 0.5N hydrochloric acid (200 L)
containing sodium chloride (10 kg) and 20% brine (200 L). The
organic layer was concentrated under reduced pressure and
azeotroped with ethyl acetate (200 L). Ethyl acetate (320 L) and
water (200 L) were added to the residue and, after stirring, the
mixture was partitioned. The organic layer was concentrated under
reduced pressure and azeotroped twice with isobutyl acetate (200
L). The residue was dissolved by heating filtered while it was hot,
and thoroughly washed with isobutyl acetate (20 L). A seed crystal
(crystal form II of compound A, 39 g) was added to the filtrate at
60.degree. C., and the mixture was stirred at the same temperature
for 1.5 hr. The mixture was stirred with heating at 80.degree. C.
for 2 hr, allowed to cool to room temperature and further stirred
for 6 hr. The precipitated solid was collected by filtration. The
obtained solid was washed with isobutyl acetate (40 L) and vacuum
dried to give a crystal of compound A (crystal form II) (29.0 kg,
yield 72%) as a white solid. This crystal was confirmed to be
equivalent to the standard product of the crystal (crystal form II
of compound A obtained in Example 2-1) by HPLC and X ray powder
diffraction (XRPD) analysis.
Example 2-3
Production of Crystal Form II of the Compound A
[0130] The crystal form II can be also produced by crystallization
according to the methods described in Examples 2-3-1 to 2-3-26.
Example 2-3-1
[0131] The compound A (200 mg) obtained in Example 1 was dissolved
in 1-butanol (2 ml) with heating under reflux. The mixture was
stirred for 17 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (125 mg, yield 63%) of compound A as a white solid.
Example 2-3-2
[0132] The compound A (200 mg) obtained in Example 1 was dissolved
in butyl acetate (2 ml) with heating under reflux. The mixture was
stirred for 17 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (102 mg, yield 51%) of compound A as a white solid.
Example 2-3-3
[0133] The compound A (200 mg) obtained in Example 1 was dissolved
in methyl isobutyl ketone (2 ml) with heating under reflux. Heptane
(2 ml) was added dropwise and the mixture was stirred for 6 hr
while allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (168 mg, yield
84%) of compound A as a white solid.
Example 2-3-4
[0134] The compound A (200 mg) obtained in Example 1 was dissolved
in ethanol (2 ml) with heating under reflux. The mixture was
stirred for 17 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (56 mg, yield 28%) of compound A as a white solid.
Example 2-3-5
[0135] The compound A (200 mg) obtained in Example 1 was dissolved
in ethyl acetate (2 ml) with heating under reflux. Heptane (1.6 ml)
was added dropwise and the mixture was stirred for 6 hr while
allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (166 mg, yield
83%) of compound A as a white solid.
Example 2-3-6
[0136] The compound A (200 mg) obtained in Example 1 was dissolved
in methyl ethyl ketone (2 ml) with heating under reflux. Heptane (4
ml) was added dropwise and the mixture was stirred for 6 hr while
allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (123 mg, yield
62%) of compound A as a white solid.
Example 2-3-7
[0137] The compound A (200 mg) obtained in Example 1 was dissolved
in 1-propanol (2 ml) with heating under reflux. The mixture was
stirred for 17 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (91 mg, yield 46%) of compound A as a white solid.
Example 2-3-8
[0138] The compound A (200 mg) obtained in Example 1 was dissolved
in isopropanol (2 ml) with heating under reflux. The mixture was
stirred for 17 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (88 mg, yield 44%) of compound A as a white solid.
Example 2-3-9
[0139] The compound A (200 mg) obtained in Example 1 was dissolved
in cumene (2 ml) with heating under reflux. The mixture was stirred
for 17 hr while allowing to cool. The precipitated solid was
collected by filtration and vacuum dried to give crystal form II
(188 mg, yield 94%) of compound A as a white solid.
Example 2-3-10
[0140] The compound A (200 mg) obtained in Example 1 was dissolved
in anisole (2 ml) with heating under reflux. The mixture was
stirred for 17 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (107 mg, yield 54%) of compound A as a white solid.
Example 2-3-11
[0141] The compound A (200 mg) obtained in Example 1 was dissolved
in acetone (2 ml) with heating under reflux. Heptane (2 ml) was
added dropwise and the mixture was stirred for 16.5 hr while
allowing to cool. Heptane (4 ml) was further added, and the mixture
was further stirred for 24 hr. The precipitated solid was collected
by filtration and vacuum dried to give crystal form II (134 mg,
yield 67%) of compound A as a white solid.
Example 2-3-12
[0142] The compound A (200 mg) obtained in Example 1 was dissolved
in ethanol (2 ml) with heating under reflux. Heptane (4 ml) was
added dropwise and the mixture was stirred for 19 hr while allowing
to cool. The precipitated solid was collected by filtration and
vacuum dried to give crystal form II (129 mg, yield 65%) of
compound A as a white solid.
Example 2-3-13
[0143] The compound A (200 mg) obtained in Example 1 was dissolved
in isopropanol (2 ml) with heating under reflux. Heptane (4 ml) was
added dropwise and the mixture was stirred for 19 hr while allowing
to cool. The precipitated solid was collected by filtration and
vacuum dried to give crystal form II (166 mg, yield 83%) of
compound A as a white solid.
Example 2-3-14
[0144] The compound A (200 mg) obtained in Example 1 was dissolved
n 1-propanol (2 ml) with heating under reflux. Heptane (4 ml) was
added dropwise and the mixture was stirred for 19 hr while allowing
to cool. The precipitated solid was collected by filtration and
vacuum dried to give crystal form II (158 mg, yield 79%) of
compound A as a white solid.
Example 2-3-15
[0145] The compound A (200 mg) obtained in Example 1 was dissolved
in isobutanol (2 ml) with heating under reflux. The mixture was
stirred for 21 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (131 mg, yield 66%) of compound A as a white solid.
Example 2-3-16
[0146] The compound A (200 mg) obtained in Example 1 was dissolved
in toluene (2 ml) with heating at 100.degree. C. The mixture was
stirred for 37 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (190 mg, yield 95%) of compound A as a white solid.
Example 2-3-17
[0147] The compound A (200 mg) obtained in Example 1 was dissolved
in methyl butyl ketone (2 ml) with heating at 60.degree. C. Heptane
(1.8 ml) was added dropwise and the mixture was stirred for 37 hr
while allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (191 mg, yield
9610 of compound A as a white solid.
Example 2-3-18
[0148] The compound A (200 mg) obtained in Example 1 was dissolved
in chloroform (1 ml) with heating at 60.degree. C. Isopropyl ether
(1.8 ml) was added dropwise and the mixture was stirred for 37 hr
while allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (184 mg, yield
92%) of compound A as a white solid.
Example 2-3-19
[0149] The compound A (200 mg) obtained in Example 1 was dissolved
in tetrahydrofuran (1 ml) by heating at 60.degree. C. Isopropyl
ether (2 ml) was added dropwise and the mixture was stirred for 41
hr while allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (144 mg, yield
72%) of compound A as a white solid.
Example 2-3-20
[0150] The compound A (200 mg) obtained in Example 1 was dissolved
in isobutanol (2 ml) with heating under reflux. Heptane (2 ml) was
added dropwise and the mixture was stirred for 21 hr while allowing
to cool. The precipitated solid was collected by filtration and
vacuum dried to give crystal form II (160 mg, yield 80%) of
compound A as a white solid.
Example 2-3-21
[0151] The compound A (200 mg) obtained in Example 1 was dissolved
in butanol (2 ml) with heating under reflux. Heptane (2 ml) was
added dropwise and the mixture was stirred for 21 hr while allowing
to cool. The precipitated solid was collected by filtration and
vacuum dried to give crystal form II (152 mg, yield 76%) of
compound A as a white solid.
Example 2-3-22
[0152] The compound A (200 mg) obtained in Example 1 was dissolved
in isobutyl acetate (2 ml) with heating under reflux. The mixture
was stirred for 21 hr while allowing to cool. The precipitated
solid was collected by filtration and vacuum dried to give crystal
form II (140 mg, yield 70%) of compound A as a white solid.
Example 2-3-23
[0153] The compound A (200 mg) obtained in Example 1 was dissolved
in isobutyl acetate (2 ml) with heating under reflux. Heptane (2
ml) was added dropwise and the mixture was stirred for 21 hr while
allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (178 mg, yield
89%) of compound A as a white solid.
Example 2-3-24
[0154] The compound A (200 mg) obtained in Example 1 was dissolved
in butyl acetate (2 ml) with heating under reflux. Heptane (1.5 ml)
was added dropwise and the mixture was stirred for 21 hr while
allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (158 mg, yield
78%) of compound A as a white solid.
Example 2-3-25
[0155] The compound A (200 mg) obtained in Example 1 was dissolved
in anisole (2 ml) by heating at 110.degree. C. Heptane (2 ml) was
added dropwise and the mixture was stirred for 21 hr while allowing
to cool. The precipitated solid was collected by filtration and
vacuum dried to give crystal form II (187 mg, yield 89%) of
compound A as a white solid.
Example 2-3-26
[0156] The compound A (200 mg) obtained in Example 1 was dissolved
in butyl acetate (2 ml) with heating under reflux. After rapid
cooling, the mixture was stirred for 2 hr. The precipitated solid
was collected by filtration and vacuum dried to give crystal form
II (131 mg, yield 66%) of compound A as a white solid.
Example 2-4
Production of Crystal Form II of the Compound A
[0157] Step 1
[0158]
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chlo-
ro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid ethyl ester (48 g, 86 mmol) obtained in Example 1, Step 5 was
dissolved in methanol (300 ml), water (5 ml) and 28% sodium
methoxide methanol solution (176 ml, 862 mmol) were added, and the
mixture was heated under reflux for 24 hr. The reaction mixture was
allowed to cool to room temperature, neutralized with 6N
hydrochloric acid and methanol was evaporated under reduced
pressure. Water was added to the obtained solution and, after
stirring, the precipitated solid was collected by filtration. The
obtained solid was dissolved in ethyl acetate, washed with water,
and dried over sodium sulfate. The mixture was filtered and the
filtrate was concentrated under reduced pressure. The obtained
residue was recrystallized from ethyl acetate-hexane to give
compound A (primary crystal 29.5 g, secondary crystal 2.8 g, in
total 32.3 g, yield 86%) as a white solid.
[0159] m.p. 151-152.degree. C.
[0160] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72 (3H,
d, J=6.5 Hz), 1.16 (3H, d, J=6.5 Hz), 2.30-2.50 (1H, m), 3.70-3.90
(1H, m), 3.90-4.00 (1H, m), 4.03 (3H, s), 4.12 (2H,s), 4.80-4.90
(1H, m), 5.19 (1H, t), 7.19-7.25 (2H, m), 7.46-7.51 (2H, m), 8.04
(1H, s), 8.88 (1H, s), 15.44 (1H, s)
[0161] MS (ESI) : M+ 448
[0162] Step 2
[0163] Compound A (32.3 g) obtained in Step 1 was dissolved in
butyl acetate (160 ml) with heating under reflux. The crystal form
II of Example 2 was seeded at 63.degree. C. and the mixture was
stirred for 3 hr while allowing to cool. The precipitated solid was
collected by filtration and vacuum dried to give the crystal of
compound A (crystal form II) (24.79 g, yield 77%) as a white
solid.
Example 2-5
Production of Crystal Form II of the Compound A
[0164] Step 1
##STR00026##
[0165]
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chlo-
ro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid ethyl ester (19 g, 33 mmol) obtained in Example 1, Step 5 was
dissolved in isopropanol (100 ml), 1N aqueous sodium hydroxide
solution (200 ml, 200 mmol) was added, and the mixture was heated
under reflux for 2.5 hr. The reaction mixture was allowed to cool
to room temperature, and the mixture was filtered through Celite.
The filtrate was acidified by adding concentrated hydrochloric
acid, and stirred at room temperature for 2 hr. The precipitated
solid was collected by filtration and vacuum dried to give
6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methyl-
propyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (12 g, yield
82%) as a pale-yellow solid.
[0166] .sup.1H NMR(DMSO-d.sub.6 400 MHz) (.delta.) ppm: 0.71(3H, d,
J=6.5 Hz), 1.13(3H, d, J=6.5 Hz), 2.36(1H, br), 3.77(1H, br),
3.94(1H, br), 4.25 (2H, s), 4.77(1H, br), 5.16 (1H, t, J=2.4 Hz),
7.19-7.23 (1H, m), 7.32-7.35 (1H, m), 7.48-7.52 (1H, m), 8.24-8.28
(2H, m), 9.00 (1H, s), 15.00 (1H, s)
[0167] Step 2
##STR00027##
[0168] The compound (12 g, 27 mmol) obtained in Step 1 was
dissolved in methanol (64 ml), 28% sodium methoxide methanol
solution (52 ml, 256 mmol) was added, and the mixture was heated
under reflux for 24 hr. The reaction mixture was allowed to cool to
room temperature and filtered through Celite. The filtrate was
concentrated under reduced pressure. The residue was acidified by
adding water (360 ml) and concentrated hydrochloric acid, and
extracted with ethyl acetate. The organic layer was washed
successively with water and saturated brine and dried over sodium
sulfate. The mixture was filtered, and the filtrate was
concentrated under reduced pressure to give a crude product (13 g)
as a brown oil. The obtained crude product (13 g) was dissolved in
isobutyl acetate (60 ml) by heating and, after seeding, the mixture
was stirred for 23 hr while allowing to cool. The precipitated
solid was collected by filtration, and vacuum dried to give
compound A (9.2 g, yield 75%) as a white solid.
[0169] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72 (3H,
d, J=6.5 Hz), 1.16 (3H, d, J=6.5 Hz), 2.30-2.50 (1H, m), 3.70-3.90
(1H, m), 3.90-4.00 (1H, m), 4.03 (3H, s), 4.12 (2H,s), 4.80-4.90
(1H, m), 5.19 (1H, t), 7.19-7.25 (2H, m), 7.46-7.51 (2H, m),
8.04(1H, s), 8.88 (1H, s), 15.44 (1H, s)
[0170] MS (ESI) : M+ 448
[0171] Step 3
##STR00028##
[0172] 2-(2,4-Difluoro-5-iodobenzoyl)-3-dimethylaminoacrylic acid
ethyl ester (20 g) obtained in Example 1, Step 2 was subject to
slurry washing with a mixed solvent of ethyl acetate (60 ml) and
hexane (40 ml) and heated under reflux. The mixture was filtered,
and the remaining solid was vacuum dried to give
7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropyl)-6-iodo-4-oxo-1,4-dihydroq-
uinoline-3-carboxylic acid ethyl ester (18 g, yield 94%) as a beige
solid.
[0173] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72(3H,
d, J=6.6 Hz), 1.10 (3H, d, J=6.6 Hz), 1.28(3H, t, J=7.0 Hz), 2.27
(1H, br), 3.77 (1H, br), 3.86(1H, br), 4.23 (2H, q, J=7.0 Hz),
4.56(1H, br), 5.12 (1H, t, J=4.9 Hz), 8.09(1H, d, J=11.1 Hz), 8.62
(1H, d, J=7.5 Hz), 8.68(1H, s)
[0174] MS(ESI): M+ 448
[0175] Step 4
##STR00029##
[0176] The compound (19 g, 42 mmol) obtained in Step 3 was
dissolved in dimethylformamide (65 ml), imidazole (3.4 g, 49.9
mmol) and tert-butyldimethylsilyl chloride (7.2 g, 47.8 mmol) were
added, and the mixture was stirred at room temperature for 1.5 hr.
Water was added to the reaction mixture, and the mixture was
extracted with ethyl acetate. The organic layer was washed
successively with water, saturated aqueous ammonium chloride
solution and saturated brine, and dried over sodium sulfate. The
organic layer was filtered, and the filtrate was concentrated under
reduced pressure to give a crude product (24 g) of
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-7-fluoro-6-iodo-
-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester as a
beige amorphous form.
[0177] .sup.1H NMR(CDCl.sub.3 400 MHz) (.delta.) ppm: -0.07(3H, s),
-0.05(3H, s), 0.77(9H, s), 0.84(3H,d, J=6.5 Hz), 1.18(3H, d, J=6.5
Hz), 1.40(3H, t, J=7.2 Hz), 2.35-2.50(1H, m), 3.85-3.95(1H, m),
3.98-4.10(2H, m), 4.30-4.40(2H, m), 7.26(1H,s), 8.64(1H, s),
8.94(1H, d, J=7.2 Hz)
[0178] MS(ESI): M+ 562
[0179] Step 5
##STR00030##
[0180] The crude product (24 g) obtained in Step 4 was dissolved in
tetrahydrofuran (200 ml) and, under an argon stream,
dibenzylidenacetonepalladium(II) (984 mg, 1.7 mmol) and
trifurylphosphine (795 mg, 3.4 mmol) were added, and a solution (56
ml, 56 mmol) of 1M 3-chloro-2-fluorobenzylzinc bromide obtained in
the same manner as in Example 1, Step 5 in tetrahydrofuran was
added dropwise at 60.degree. C. After the completion of the
dropwise addition, the mixture was stirred with heating at the same
temperature for 2 hr. The reaction mixture was allowed to cool to
room temperature, saturated aqueous ammonium chloride solution was
added, and filtered through Celite, and the filtrate was extracted
twice with ethyl acetate. The organic layer was washed successively
with water (twice) and saturated brine, and dried over magnesium
sulfate. The organic layer was filtered, and the filtrate was
concentrated under reduced pressure to give a crude product (30 g)
of
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chloro-2-f-
luorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ethyl ester as a brown paste.
[0181] Step 6
##STR00031##
[0182] The crude product (30 g) obtained in Step 5 was dissolved in
isopropanol (150 ml), 1N aqueous sodium hydroxide solution (300 ml,
300 mmol) was added, and the mixture was heated under reflux for
2.5 hr. The reaction mixture was allowed to cool to room
temperature, and the mixture was filtered through Celite. The
filtrate was acidified by adding concentrated hydrochloric acid,
and the mixture was stirred at room temperature for 2 hr. The
precipitated solid was collected by filtration and vacuum dried to
give a crude product (18 g) as a beige solid. The obtained crude
product (18 g) was suspended in butyl acetate (90 ml), and
subjected to slurry stirring with heating under reflux for 1 hr.
The suspension was allowed to cool to room temperature, filtered
and vacuum dried to give
6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-US)-1-hydroxymethyl-2-methylpropyl-
)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (11 g, yield 62%
(relative to Step 3)) as a white solid.
[0183] .sup.1H NMR(DMSO-d.sub.6 400 MHz) (.delta.) ppm: 0.71 (3H,
d, J=6.5 Hz), 1.13 (3H, d, J=6.5 Hz), 2.36 (1H, br), 3.77(1H, br),
3.94 (1H, br), 4.25 (2H, s), 4.77(1H, br), 5.16 (1H,t, J=2.4 Hz),
7.19-7.23(1H, m), 7.32-7.35 (1H, m), 7.48-7.52(1H, m), 8.24-8.28
(2H, m), 9.00 (1H, s), 15.00 (1H, s)
[0184] MS(ESI): M+ 436
[0185] Step 7
##STR00032##
[0186] The compound (11 g, 26 mmol) obtained in Step 6 was
dissolved in methanol (60 ml), 28% sodium methoxide methanol
solution (52 ml, 256 mmol) was added, and the mixture was heated
under reflux for 24 hr. The reaction mixture was allowed to cool to
room temperature and filtered through Celite, and the filtrate was
concentrated under reduced pressure. The residue was acidified by
adding water (330 ml) and concentrated hydrochloric acid, and the
mixture was extracted with ethyl acetate. The organic layer was
washed successively with water and saturated brine, and dried over
sodium sulfate. The mixture was filtered, and the filtrate was
concentrated under reduced pressure to give a crude product (12 g)
as a brown oil. The obtained crude product (12 g) was dissolved in
isobutyl acetate (60 ml) by heating under reflux. A seed crystal
(crystal form II of compound A) was seeded, and the mixture was
stirred for 23 hr while allowing to cool. The precipitated solid
was collected by filtration and vacuum dried to give compound A
(8.2 g, yield 71%) as a white solid.
[0187] .sup.1H NMR (DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72 (3H,
d, J=6.5 Hz), 1.16 (3H, d, J=6.5 Hz), 2.30-2.50 (1H, m), 3.70-3.90
(1H, m), 3.90-4.00 (1H, m), 4.03 (3H, s), 4.12 (2H,s), 4.80-4.90
(1H, m), 5.19 (1H, t), 7.19-7.25 (2H, m), 7.46-7.51 (2H, m),
8.04(1H, s), 8.88 (1H, s), 15.44 (1H, s)
[0188] MS (ESI) : M+ 448
[0189] Step 8
[0190] Compound A (7.66 g) obtained in Step 7 and compound A (9.17
g) obtained in Step 2 were dissolved in isobutyl acetate (84 ml) by
heating under reflux and the mixture was stirred for 16 hr while
allowing to cool. The precipitated solid was collected by
filtration and vacuum dried to give crystal form II (14.73 g, yield
88%) of compound A as a white solid.
Example 2-6
Production of Crystal Form II of the Compound A
[0191] Step 1
##STR00033##
[0192] 2,4-Difluorobenzoic acid (100 g, 633 mmol) was dissolved in
trifluoromethanesulfonic acid (400 ml) and N-iodosuccinimide (157
g, 696 mmol) was added by portions at not more than 5.degree. C.
After the completion of the addition, the mixture was stirred at
50.degree. C. for 1.5 hr. The reaction mixture was poured into iced
water, and the mixture was stirred for 1 hr. The precipitated solid
was collected by filtration, washed successively with water and
hexane, and vacuum dried to give 2,4-difluoro-5-iodobenzoic acid
(179 g yield quantitative) as a white solid.
[0193] .sup.1H NMR(CDCl.sub.3 300MHz) (.sigma.) ppm: 6.94(1H, dd,
J=10.3, 10.3 Hz), 8.46 (1H, d, J=7.5 Hz)
[0194] Step 2
##STR00034##
[0195] The compound (28 g, 100 mmol) obtained in Step 1 was
dissolved in ethyl acetate (300 ml), oxalyl chloride (11 ml, 122
mmol) and dimethylformamide (catalytic amount) were added, and the
mixture was stirred at room temperature for 2 hr. The filtrate was
concentrated under reduced pressure and azeotroped with toluene.
The residue was dissolved in tetrahydrofuran (100 ml), this
solution was added dropwise to a solution of ethyl
3,3-dimethylaminoacrylate (17 g, 120 mmol) and triethylamine (21
ml, 150 mmol) in tetrahydrofuran (100 ml), and the mixture was
heated under reflux for 3 hr. The reaction mixture was allowed to
cool and ethyl acetate (200 ml) was added. The mixture was washed
successively with water (twice) and saturated brine, and dried over
sodium sulfate. The mixture was filtered and the filtrate was
concentrated under reduced pressure. The obtained residue was
subject to slurry stirring with a mixed solvent of diethyl ether
(50 ml) and hexane (50 ml). The mixture was filtered and the
remaining solid was vacuum dried to give a crude product (26 g,
yield 63%) of 2-(2,4-difluoro-5-iodobenzoyl)-3-dimethylaminoacrylic
acid ethyl ester as a yellow solid.
[0196] Step 3
##STR00035##
[0197] The crude product (22 g, 55 mmol) obtained in Step 2 was
dissolved in tetrahydrofuran (110 ml), (S)-(+)-valinol (6.8 g, 65.8
mmol) was added, and the mixture was stirred with heating at
50.degree. C. for 30 min. The reaction mixture was concentrated
under reduced pressure, and the residue was dissolved in ethyl
acetate (100 ml), washed successively with water and saturated
brine, and dried over magnesium sulfate. The mixture was filtered
and the filtrate was concentrated under reduced pressure. The
obtained residue was dissolved in dimethylformamide (80 ml),
potassium carbonate (19 g, 137 mmol) was added, and the mixture was
stirred with heating at 60.degree. C. for 1.5 hr. The reaction
mixture was allowed to cool to room temperature and concentrated
under reduced pressure. Water (250 ml) was added to the obtained
residue and the mixture was stirred at room temperature for 30 min.
The precipitated solid was collected by filtration. The obtained
solid was washed successively with a mixed solvent of water (100
ml), ethyl acetate (10 ml) and hexane (40 ml) and vacuum dried to
give
7-fluoro-1-((S)-1-hydroxymethyl-2-methylpropyl)-6-iodo-4-oxo-1,4-dihydroq-
uinoline-3-carboxylic acid ethyl ester (22 g, yield 88%) as a
pale-yellow solid.
[0198] .sup.1H NMR(DMSO-d.sub.6 300 MHz) (.delta.) ppm: 0.72(3H, d,
J=6.6 Hz), 1.10 (3H, d, J=6.6 Hz), 1.28(3H, t, J=7.0 Hz), 2.27 (1H,
br), 3.77 (1H, br), 3.86(1H, br), 4.23 (2H, q, J=7.0 Hz), 4.56(1H,
br), 5.12 (1H, t, J=4.9 Hz), 8.09(1H, d, J=11.1 Hz), 8.62 (1H, d,
J=7.5 Hz), 8.68(1H, s)
[0199] MS(ESI): M+ 448
[0200] Step 4
##STR00036##
[0201] The compound (22 g, 48 mmol) obtained in Step 3 was
dissolved in dimethylformamide (60 ml), imidazole (3.9 g, 57.7
mmol) and tert-butyldimethylsilyl chloride (8.0 g, 53.0 mmol) were
added, and the mixture was stirred at room temperature for 1.5 hr.
The reaction mixture was concentrated under reduced pressure, and
the obtained residue was dissolved in ethyl acetate (200 ml),
washed successively with water (twice) and saturated brine, and
dried over sodium sulfate. The mixture was filtered and the
filtrate was concentrated under reduced pressure. The obtained
residue was purified by silica gel chromatography (ethyl
acetate:hexane=3:7 to 4:6) to give
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-7-fluoro-6-iodo-
-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester (25 g,
yield 92%) as a white wax.
[0202] .sup.1H NMR(CDCl.sub.3 400 MHz) (.delta.) ppm: -0.07(3H, s),
-0.05(3H, s), 0.77(9H, s), 0.84(3H,d, J=6.5 Hz), 1.18(3H, d, J=6.5
Hz), 1.40(3H, t, J=7.2 Hz), 2.35-2.50(1H, m), 3.85-3.95(1H, m),
3.98-4.10(2H, m), 4.30-4.40(2H, m), 7.26(1H,s), 8.64(1H, s),
8.94(1H, d, J=7.2 Hz)
[0203] MS(ESI): M+ 562
[0204] Step 5
##STR00037##
[0205] The compound (25 g, 44 mmol) obtained in Step 4 was
dissolved in tetrahydrofuran (200 ml) and, under an argon stream,
dibenzylidenacetonepalladium(II) (1.0 g, 1.8 mmol) and
trifurylphosphine (824 mg, 3.5 mmol) were added. A solution (58 ml,
58 mmol) of 1M 3-chloro-2-fluorobenzylzinc bromide obtained in the
same manner as in Example 1, Step 5 in tetrahydrofuran was added
dropwise at 60.degree. C. After the completion of the dropwise
addition, the mixture was heated under reflux for 3 hr. The
reaction mixture was allowed to cool to room temperature, ethyl
acetate (200 ml) was added, washed successively with 1N
hydrochloric acid, water, saturated aqueous sodium hydrogen
carbonate, water and saturated brine, and dried over sodium
sulfate. The mixture was filtered and the filtrate was concentrated
under reduced pressure. The obtained residue was purified by silica
gel chromatography (ethyl acetate:hexane=4:6 to 1:1) to give
1-((S)-1-tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chloro-2-f-
luorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ethyl ester (17 g, yield 68%) as a pale-yellow oil.
[0206] .sup.1H NMR(CDCl.sub.3 400 MHz) (.delta.) ppm: -0.09(3H, s),
-0.05(3H, s), 0.75(9H, s), 0.85(3H,d, J=6.7 Hz), 1.18(3H, d, 6.7
Hz), 1.39(3H, t, J=7.1 Hz), 2.45(1H, br), 3.89-3.92(1H, m),
3.98-4.02(1H, m), 4.07-4.12(1H, m), 4.12(2H, s), 4.34-4.41(2H, m),
6.96-7.00(1H, m), 7.03-7.05(1H, m), 7.21-7.24(1H, m), 7.26-7.29(1H,
m), 8.39(1H, d, J=8.8 Hz), 8.63(1H, s)
[0207] Step 6
##STR00038##
[0208] The compound (17 g, 30 mmol) obtained in Step 5 was
dissolved in methanol (120 ml), 28% sodium methoxide methanol
solution (62 ml, 304 mmol) was added, and the mixture was heated
under reflux for 19 hr. The reaction mixture was allowed to cool to
room temperature, water (200 ml) was added, and methanol was
evaporated under reduced pressure. The residue was acidified by
adding concentrated hydrochloric acid, extracted with ethyl
acetate, and dried over sodium sulfate. The mixture was filtered,
and the filtrate was concentrated under reduced pressure to give a
crude product (14 g) of compound A as a pale-yellow oil.
[0209] Step 7
[0210] Compound A (14.11 g) obtained in Step 6 was suspended in a
mixed solvent of ethyl acetate (20 ml) and hexane (20 ml) at room
temperature, a seed crystal (crystal form II of compound A) was
seeded, and the mixture was stirred for 1 hr. The suspension was
filtered, and the remaining solid was vacuum dried to give compound
A (crystal form II, 10.40 g, yield 77%) as a white solid.
Example 3
Production of Crystal Form III of the Compound A
Example 3-1
Production of Crystal Form III of the Compound A
[0211] The crystal form II of compound A (10.0 g, 22.3 mmol)
obtained in Example 2-2 was added to isobutyl acetate (30 mL) and
the crystal was dissolved by heating under reflux. The solution was
cooled to 90.degree. C., and stirred for 5 hr to allow
precipitation of crystals. This solution was further allowed to
cool to room temperature, and further stirred for 12 hr. The
precipitated crystal was collected by filtration. The obtained
crystal was washed with isobutyl acetate (10 mL) and vacuum dried
to give a white crystal (9.85 g, yield 98.5%). Since this crystal
was confirmed to be different from crystal form II by XRPD
analysis, a crystal showing the XRPD chart (FIG. 1) as this crystal
was taken as crystal form III.
Example 3-2
Production of Crystal Form III of the Compound A
[0212] The crystal form II of compound A (250 g, 558 mmol) obtained
in Example 2-2 was added to isobutyl acetate (750 mL). A seed
crystal (12.5 g) of the crystal form III of compound A obtained in
Example 3 was added at room temperature and the mixture was stirred
for 17 hr. The precipitated crystal was collected by filtration.
The obtained crystal was washed with isobutyl acetate (250 mL), and
vacuum dried to give the object product (crystal form III, 259 g,
yield 98.6%) as a white crystal. This crystal was confirmed to be
equivalent to the standard product of the crystal (crystal form III
of compound A obtained in Example 3-1) by XRPD analysis.
Example 3-3
Production of Crystal Form III of the Compound A
[0213] Compound A (crystal form II, 10.0 g, 22.3 mmol) obtained in
Example 2-2 was added to isopropanol (30 mL), and the mixture was
heated under reflux to dissolve the crystal. The solution was
cooled to 70.degree. C., a seed crystal (10 mg) of the crystal form
III of compound A obtained in Example 3-1 was added, and the
mixture was stirred for 5 hr. This mixture was further allowed to
cool to room temperature, stirred for 12 hr, and the crystal was
collected by filtration. The obtained crystal was washed with
isopropanol (10 mL), and vacuum dried to give the object product
(crystal form III, 9.72 g, yield 97.2%) as a white crystal. This
crystal was confirmed to be equivalent to the standard product of
the crystal (crystal form III of compound A obtained in Example
3-1) by XRPD analysis.
Example 3-4
Production of Crystal Form III of Compound A
[0214] The crystal form II of compound A (7.00 g, 15.6 mmol)
obtained in Example 2-2 was added to a mixed solution of ethanol
(52.5 mL) and water (7 mL) and dissolved by heating. Water (28 mL)
was added, a seed crystal (10 mg) of the object product was added
at 70.degree. C. and the mixture was stirred for 4 hrs. After
allowing to cool to room temperature, the mixture was ice-cooled
and further stirred for 2 hrs, and the crystals were collected by
filtration. The obtained crystals were washed with a mixed solution
of cool ethanol (8.4 mL) and water (5.6 mL) and vacuum dried to
give the object product as white crystals (crystal form III, 6.77
g, yield 96.8%). This crystal was confirmed to be equivalent to the
standard product (Example 3-1) by XRPD analysis.
Experimental Example
[0215] The property values of each crystal form were determined by
the following analysis tests, and the stability test of each
crystal form was performed using them as indices.
[0216] Sample
[0217] Unless otherwise specified, the aforementioned crystal
(crystal form I) obtained in Reference Example 1, the crystal
(crystal form II) obtained in Example 1 and the crystal (crystal
form III) obtained in Example 3-1 were used as samples.
[0218] Analysis Test 1. X-Ray Powder Diffractometry
[0219] This test aims at obtaining X-ray powder diffraction
patterns to specify the crystal form of the crystals obtained in
Reference Example 1, Example 1 and Example 3-1. The diffraction
patterns are utilized to specify the crystal form, evaluate the
stability, to determine the purity and the like.
[0220] A sample was fixed to an aluminum cell, and the measurement
was performed using an X-ray powder diffractometer (RINT 2000/PC
Ultima.sup.+, manufactured by Rigaku Corporation, X-ray source:
Cu--K.alpha.1 ray, tube voltage: 40 kV, tube electric current: 40
mA, scan speed: 5.degree. per min, step width: 0.02.degree.,
diffraction angle: 5-40.degree.), based on which the diffraction
patterns were obtained. The obtained diffraction patterns are shown
in FIG. 1.
[0221] As shown in FIG. 1, X-ray powder diffraction patterns
obtained from respective samples were different.
[0222] Therefore it was confirmed that the crystals obtained in
Reference Example 1, Example 1 and Example 3-1 were distinct from
each other, and show characteristic diffraction patterns as shown
in the X-ray powder diffraction pattern. Therefore, in the present
specification, they were named as crystal form I, crystal form II
and crystal form III, based on these X-ray powder diffraction
patterns.
[0223] For specification of the crystal form, the diffraction peak
characteristic of each crystal may be evaluated in a comprehensive
manner based on the diffraction chart in FIG. 1.
[0224] The main diffraction peaks and characteristic diffraction
peaks specified from the diffraction patterns in FIG. 1 are shown
below.
[0225] Crystal Form I
[0226] Main diffraction peak:2.theta.=6.58, 14.40, 14.64, 15.24,
16.48, 19.16, 20.90, 21.14, 22.24, 24.74, 25.64, 26.12,
27.20.degree.;
[0227] Characteristic diffraction peak:2.theta.=6.58, 14.40, 19.16,
20.90, 21.14.degree..
[0228] Crystal Form II
[0229] Main diffraction peak:2.theta.=6.56, 9.04, 13.20, 14.62,
15.24, 16.48, 19.86, 20.84, 21.22, 22.24, 25.22, 25.96, 26.12,
27.34.degree.;
[0230] Characteristic diffraction peak:2.theta.=6.56, 13.20, 19.86,
20.84, 21.22, 25.22.degree..
[0231] Crystal Form III
[0232] Main diffraction peak:2.theta.=8.54, 14.02, 15.68, 15.90,
16.00, 17.06, 17.24, 17.84, 18.12, 19.50, 19.90, 22.26, 22.68,
23.02, 24.16, 24.76, 25.18, 25.74, 25.98, 27.50, 28.80, 30.38,
30.72, 32.54.degree.;
[0233] Characteristic diffraction peak:2.theta.=8.54, 14.02, 15.68,
17.06, 17.24, 24.16, 25.74.degree..
[0234] 2. Thermal Analysis
[0235] This test aims at the measurement of the enthalpy and
extrapolated onset temperature at an endothermic peak on the
Differential Scanning Calorimetry (DSC) measurement curve. These
values are among the indices of the stability of the
above-mentioned crystal form I, crystal form II and crystal form
III, and can be used as an index to specify the crystal form.
[0236] 2.1. Enthalpy and Extrapolated Onsettemperature of Crystal
Form I and Crystal Form II
[0237] CCrystal form I and crystal form II were subjected to
measurement using a Differential Scanning Calorimetry (DSC)
measurement apparatus (DSC8240, manufactured by Rigaku
Corporation), under atmosphere, measurement sample 5.+-.1 mg,
temperature rise rate: 10.degree. C./min, aluminum open pan, and
alumina oxide as a reference. The enthalpy and extrapolated onset
temperature at an endothermic peak on the obtained DSC curve were
determined.
[0238] 2.2. Enthalpy and Extrapolated Onset Temperature of Crystal
Form III
[0239] Crystal form III was subjected to measurement using a DSC
measurement apparatus (DSC8240, manufactured by Rigaku
Corporation), under atmosphere, measurement sample 5.0.+-.0.5 mg,
temperature rise rate: 5.degree. C./min, aluminum closed pan, and
alumina oxide as a reference. The enthalpy and extrapolated onset
temperature at an endothermic peak on the obtained DSC curve were
determined.
[0240] The results are shown in Table 1.
TABLE-US-00001 TABLE 1 DSC curve at endothermic peak on enthalpy
and extrapolated onset temperature Endothermic peak Extrapolated
onset Crystal form Enthalpy (J/g) temperature (.degree. C.) Crystal
form I 51.080 150.3 Crystal form II 53.542 151.2 Crystal form III
81.404 162.1
[0241] As shown in Table 1, crystal form III shows greatest
enthalpy and-highest extrapolated onset temperature among three
crystal formscrystal form I. Thus, crystal form III was confirmed
to be most stable form.
[0242] 3. Purity Test
[0243] This test aims at measurement of the purity of compound A.
The purity can be used as indices of chemical stability.
[0244] 3.1. Purity of Compound of Crystal Form I and Crystal Form
II
[0245] Each sample (crystal form I and crystal form II, ca. 10 mg)
was dissolved in acetonitrile to make an amount of 10 mL and used
as a sample solution. This solution (10 .mu.L) was applied to high
performance liquid chromatography (HPLC) under the following
conditions. The peak area of each sample solution was measured by
automatic integration, and the purity was determined by the
following formula. The purity is shown in the Tables 5 and 6
below.
Purity (%)=100-(A.sub.sum/A.sub.s).times.100
[0246] As: total peak area of peaks obtained from sample
solution
[0247] Asum: total peak area of peaks other than the main peak
obtained from sample solution
[0248] Test Conditions
[0249] Detector: UV absorptiometer (wavelength: 259 nm)
[0250] Column: CAPCELL PAK MG (inner diameter 4.6 cm, length 15 cm,
particle size 5 .mu.m, manufactured by Shiseido Co., Ltd.
[0251] Column temperature: constant temperature around 40.degree.
C.
[0252] Mobile phase A: trifluoroacetic acid solution (1:1000)
[0253] Mobile phase B: solution of trifluoroacetic acid in
acetonitrile (1:1000)
[0254] Gradient program: As shown in the following Table 2, the
mixing ratio of mobile phase A and mobile phase B is changed to
control concentration gradient.
TABLE-US-00002 TABLE 2 Time (min) Mobile Mobile after injection
phase A (%) phase B (%) 0 55 45 0-5 55.fwdarw.52 45.fwdarw.48 5-15
52 48 15-25 52.fwdarw.20 48.fwdarw.80 25-35 20 80 35-36
20.fwdarw.55 80.fwdarw.45 36-45 55 45 Flow rate: 1 mL/min
[0255] 3.2. Purity of Compound of Crystal Form III
[0256] A sample (crystal form III, ca. 50 mg) was dissolved in a
mixture (4:1) of mobile phase B and mobile phase A to make an
amount of 50 mL, which was used as a sample solution. This solution
(1 mL) was precisely measured and a mixture (4:1) of mobile phase
Band mobile phase A was added to precisely make an amount of 100
mL, which was used as a standard solution. The sample solution and
standard solution (15 .mu.L) was applied to high performance liquid
chromatography (HPLC) under the following conditions. The peak area
of each solution was measured by automatic integration, and the
purity was determined by the following formula. The purity is shown
in the Table 7 below.
Purity (%)=100-(A.sub.sum/A.sub.r)
[0257] A.sub.r: peak area of main peak obtained from standard
solution
[0258] A.sub.sum: total peak area of peaks other than the main peak
obtained from sample solution
[0259] Test Conditions
[0260] Detector: UV absorptiometer (wavelength: 259 nm)
[0261] Column: Waters XTerra MC C18 (inner diameter 4.6 cm, length
5 cm, particles diameter 2.5 .mu.m, manufactured by Waters)
[0262] Column temperature: constant temperature around 40.degree.
C.
[0263] Mobile phase A: phosphoric acid is added to dipotassium
hydrogenphosphate solution (1.fwdarw.1149) to adjust pH to 7.0
[0264] Mobile phase B: acetonitrile
[0265] Gradient program: As shown in the following Table 3, the
mixing ratio of mobile phase A and mobile phase B is changed to
control concentration gradient.
TABLE-US-00003 TABLE 3 Time (min) Mobile Mobile after injection
phase A (%) phase B (%) 0-15 58 42 15-35 58.fwdarw.20 42.fwdarw.80
35-45 20 80 45-46 20.fwdarw.58 80.fwdarw.42 46-55 58 42 Flow rate:
0.9 mL/min
[0266] 4. Solubility Test
[0267] This test aims at measurement of solubility of the crystal
in various test solutions and under various pHs. The solubility is
one of the indices of the stability of the above-mentioned crystal
form I, crystal form II and crystal form III and can be used also
as a reference indices of absorbability of crystal form by living
organisms.
[0268] Each sample (crystal form I type I, crystal form II and
crystal form III, ca. 10 mg) was placed in a 10 mL centrifuge tube
together with the following test solution (5 mL) and shaken with a
shaker (SR-1M; manufactured by Tietech Co., Ltd.) for 14 hours.
After shaking, the mixture was centrifuged (3000 rpm, 20 min) and
the supernatant was filtered through 0.2 .mu.m pore size--13 mm
diameter polytetrafluoroethylene disk filter (Millex-LG;
manufactured by Millipore Corporation). The measurement was
performed by high performance liquid chromatography (HPLC). The
results are shown in Table 4.
TABLE-US-00004 TABLE 4 Solubility Test Solubility (.mu.g/mL) Test
solution pH Crystal form II Crystal form III Purified -- 0.5
<0.1 water Japanese 1.2 0.9 <0.1 Pharmacopoeia 1st fluid
.sup.1) Japanese 6.8 5.8 2.4 Pharmacopoeia 2nd fluid .sup.2)
McIlvaine .sup.3) 2.2 1.9 <0.1 4 0.8 <0.1 5 0.4 <0.1 6 1.0
0.7 6.8 6.3 0.7 8 84 23 .sup.1) Japanese Pharmacopoeia, General
Test Method, Disintegration Test Method, 1st fluid. Hydrochloric
acid (7.0 mL) and water are added to sodium chloride (2.0 g) to
make an amount of 1000 mL. This solution is transparent and
colorless and has a pH of about 1.2. .sup.2) Japanese
Pharmacopoeia, General Test Method, Disintegration Test Method, 2nd
fluid. 0.2 mol/L sodium hydroxide sample (118 mL) and water are
added to 0.2 mol/L potassium disodium phosphate sample (250 mL) to
make an amount of 1000 mL. This solution is transparent and
colorless and has a pH of about 6.8. .sup.3) McIlvaine buffer
obtained by mixing disodium hydrogenphosphate and citric acid at a
given ratio to adjust to a given pH. From the above-mentioned
results, it was confirmed that crystal form II has higher
solubility then crystal form III.
[0269] 5. Stability Test
[0270] A stability test of each sample was performed under the
following preservation conditions. The results of crystal form I
are shown in Table 5, the results of crystal form II are shown in
Table 6, and the results of crystal form III are shown in Table
7.
[0271] As shown in Table 6 and Table 7, crystal form II and crystal
form III did not show any difference in the test results under all
preservation conditions, as compared to the initial sample. In
contrast, as shown in Table 5, crystal form I showed changes in the
X-ray powder diffraction pattern obtained from sample after
preservation under preservation condition #3 (80.degree. C.,
preservation in an open container for 3 days) and preservation
condition #5 (60.degree. C., preservation in an open container for
3 weeks), and the X-ray powder diffraction pattern of crystal form
I was observed to have overlapped with the X-ray powder diffraction
pattern derived from crystal form II. Thus, it was evaluated that a
part of the sample showed crystal transition to crystal form II
during preservation. The X-ray powder diffraction patterns of the
samples preservation sample under preservation conditions #1-6 of
crystal form I are shown in FIG. 2.
TABLE-US-00005 TABLE 5 Results of stability test of crystal form I
Preservation Thermal conditions Appearance Purity XRD analysis 1
Initial -- 99.1% Diffraction Endothermic pattern of peak crystal
(extrapolated form I onset temperature 150.3.degree. C.) 2
80.degree. C. No change 99.1% No change No change in Closed in in
DSC curve container appearance diffraction Preserved pattern for 3
days 3 80.degree. C. No change 99.1% Overlap of No change in Open
in diffraction DSC curve container appearance patterns of Preserved
crystal for 3 days form I and crystal form II 4 60.degree. C. No
change 99.1% No change No change in Closed in in DSC curve
container appearance diffraction Preserved pattern for 3 weeks 5
60.degree. C. No change 99.1% Overlap of No change in Open in
diffraction DSC curve container appearance patterns of Preserved
crystal for 3 weeks form I and crystal form II 6 60.degree. C./75%
No change 99.1% No change No change in R.H. in in DSC curve Open
appearance diffraction container pattern Preserved for 3 weeks
R.H.: relative humidity XRD: X-ray powder diffractometry
TABLE-US-00006 TABLE 6 Results of stability test of crystal form II
Preservation Thermal conditions Appearance Purity XRD analysis 1
Initial -- 98.9% Diffraction Endothermic pattern of peak crystal
(extrapolated form II onset temperature 151.2.degree. C.) 2
80.degree. C. No change 98.9% No change No change in Closed in in
DSC curve container appearance diffraction Preserved pattern for 3
days 3 80.degree. C. No change 98.8% No change No change in Open in
in DSC curve container appearance diffraction Preserved pattern for
3 days 4 60.degree. C. No change 98.9% No change No change in
Closed in in DSC curve container appearance diffraction Preserved
pattern for 3 weeks 5 60.degree. C. No change 98.8% No change No
change in Open in in DSC curve container appearance diffraction
Preserved pattern for 3 weeks 6 60.degree. C./75% No change 98.9%
No change No change in R.H. in in DSC curve Open appearance
diffraction container pattern Preserved for 3 weeks R.H.: relative
humidity XRD: X-ray powder diffractometry
TABLE-US-00007 TABLE 7 Results of stability test of crystal form
III Preservation Thermal conditions Appearance Purity XRD analysis
1 Initial -- 98.71% Diffraction Endothermic pattern of peak crystal
(extrapolated form III onset temperature 162.1.degree. C.) 2
80.degree. C. No change 98.68% No change No change in Closed in in
DSC curve container appearance diffraction Preserved pattern for 3
days 3 80.degree. C. No change 98.69% No change No change in Open
in in DSC curve container appearance diffraction Preserved pattern
for 3 days 4 60.degree. C. No change 98.67% No change No change in
Closed in in DSC curve container appearance diffraction Preserved
pattern for 3 weeks 5 60.degree. C. No change 98.66% No change No
change in Open in in DSC curve container appearance diffraction
Preserved pattern for 3 weeks 6 60.degree. C./75% No change 98.65%
No change No change in R.H. in in DSC curve Open appearance
diffraction container pattern Preserved for 3 weeks R.H.: relative
humidity XRD: X-ray powder diffractometry
[0272] From the results of the above-mentioned stability test, it
was observed that the crystal form I was unstable but crystal form
II and crystal form III were extremely stable under various
preservation conditions. Therefore, it was evidenced that crystal
form II and crystal form III are preferable for use as a
pharmaceutical product and the like.
[0273] As for the absorbability by living organisms, crystal form
II is more preferable, and crystal form III is more preferable
because it is the most stable crystal.
[0274] Since crystal form II and crystal form III are both stable,
a mixed crystal of them can be used for the present invention.
Experimental Example
[0275] The following explains evaluation methods of the HIV
integrase inhibitory activity of a crystal or a mixed crystal of
compound A of the present invention.
[0276] (i) Construction of Recombinant Integrase Gene Expression
System
[0277] The 185th phenylalanine of HIV integrase full length gene
(J. Virol., 67, 425-437 (1993)) was substituted by histidine and
inserted into the restriction enzyme NdeI and XhoI sites of the
plasmid pET21a(+) (manufactured by Novagen), whereby an integrase
expression vector pET21a-IN-F185H was constructed.
[0278] (ii) Production and Purification of Integrase Protein
[0279] Escherichia coli recombinant BL21(DE3) transformed with
plasmid pET21a-IN-F185H obtained in (1) was shake cultured at
30.degree. C. in a liquid medium containing ampicillin. When the
culture reached the logarithmic growth phase,
isopropyl-.beta.-D-thiogalactopyranoside was added to promote
expression of integrase gene. The culture was continued for 3 hr to
promote accumulation of the integrase protein. The recombinant E.
coli was collected in pellets by centrifugal separation and
preserved at -80.degree. C.
[0280] The E. coli was suspended in Lysis buffer (20 mM HEPES 7.5),
5 mM DTT, 10 mM CHAPS, 10% glycerol) containing 1M sodium chloride
and subjected to repeat pressurization and depressurization for
rupture, and centrifugal separation at 4.degree. C.,
40,000.times.g, 60 min to recover a water-soluble fraction is
(supernatant). This was diluted 10-fold with Lysis buffer free of
sodium chloride, mixed with SP-Sepharose (manufactured by Pharmacia
Corporation) and stirred at 4.degree. C. for 60 min to allow
adsorption of integrase protein to the resin. The resin was washed
with Lysis buffer containing 100 mM sodium chloride and the
integrase protein was eluted with Lysis buffer containing 1M sodium
chloride.
[0281] The eluted integrase protein solution was applied to a
Superdex 75 (Pharmacia Corporation) column for gel filtration. The
protein was eluted with Lysis buffer containing 1M sodium
chloride.
[0282] The obtained fractions of the integrase protein were
collected and preserved at -80.degree. C.
[0283] (iii) Preparation of DNA Solution
[0284] The following DNA synthesized by Greiner was dissolved in TE
buffer (10 mM Tris-hydrochloric acid (pH 8.0), 1 mM EDTA) and mixed
with donor DNA, target DNA, and each complementary strand (+ and -
strands) to 1 .mu.m. The mixture was heated at 95.degree. C. for 5
min, 80.degree. C. for 10 min, 70.degree. C. for 10 min, 60.degree.
C. for 10 min, 50.degree. C. for 10 min and 40.degree. C. for 10
min and preserved at 25.degree. C. to give a double stranded DNA,
which was used for the test.
[0285] Donor DNA (- strand having biotin attached to the 5' so
terminal)
[0286] Donor + strand: 5'-Biotin-ACC CTT TTA GTC AGT GTG GAA AAT
CTC TAG CA-3' (SEQ ID NO:1)
[0287] Donor - strand: 5'-ACT GCT AGA GAT TTT CCA CAC TGA CTA AAA
G-3' (SEQ ID NO:2)
[0288] Target DNA (+, - strands both having digoxigenin added at 3'
terminal)
[0289] Target + strand: 5'-TGA CCA AGG GCT AAT TCA CT-Dig-3' (SEQ
ID NO:3)
[0290] Target - strand: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3' (SEQ
ID NO:4)
[0291] (iv) Determination of Enzyme (HIV Integrase) Inhibitory
Activity
[0292] The donor DNA was diluted with TE buffer to 10 nM, of which
50 .mu.l was added to each well of streptavidin-coated microtiter
plate (manufactured by Roche) and allowed to adsorb at 37.degree.
C. for 60 min. The DNA was then washed with phosphate buffer
(Dulbecco PBS, Sanko Junyaku Co., Ltd.) containing 0.1% Tween 20
and phosphate buffer. Then, a reaction mixture (70 .mu.l, see the
following * for the composition), a test substance (10 .mu.l)
diluted with the reaction mixture and 100 .mu.g/ml integrase
protein (10 .mu.l) were added to each well and reacted at
37.degree. C. for 60 min.
[0293] Then, 50 nM target DNA (10 .mu.l) was added, reacted at
37.degree. C. for 10 min and washed with phosphate buffer
containing 0.1% Tween 20 to stop the reaction.
[0294] Then, 100 mU/ml peroxidase labeled anti-digoxigenin antibody
solution (manufactured by Roche, 100 .mu.l) was added, and the
mixture was reacted at 37.degree. C. for 60 min, followed by
washing with phosphate buffer containing 0.1% Tween 20.
[0295] A peroxidase color solution (manufactured by Bio Rad, 100
.mu.l) was added and allowed to react at room temperature for 4
min. The color reaction was stopped by adding 1N sulfuric acid (100
.mu.l). The absorbance at 450 nm was measured.
[0296] The HIV integrase inhibitory activity (IC.sub.50) of the
compound A of the present invention was calculated from the
inhibition rate according to the following formula. The results are
shown in Table 8.
Inhibition rate
(%)=[1-(Object-Blank)/(Control-Blank)].times.100
[0297] Object; absorbance of well in the presence of test
compound
[0298] Control; absorbance of well in the absence of test
compound
[0299] Blank; absorbance of well in the absence of test compound,
in the absence of integrase protein
[0300] *Composition of the reaction mixture: 30 mM
morpholinopropanesulfonic acid (MOPS), 5 mM MgCl.sub.2, 3 mM
dithiothreithol (DTT), 0.1 mg/mL bovine serum albumin (BSA), 5%
glycerol, 10% dimethyl sulfoxide (DMSO), 0.01% Tween 20
TABLE-US-00008 TABLE 8 Compound No. Enzyme activity IC.sub.50
(.mu.M) Compound A 0.0029
[0301] Evaluation of Antivirus Activity
[0302] The effect of combined use of a crystal or a mixed crystal
of compound A of the present invention and existent anti-HIV agents
can be determined in the following manner.
[0303] For example, the effect of combined use of two agents from
existent nucleoside reverse transcriptase inhibitors (zidovudine,
lamivudine, tenofovir), non-nucleoside reverse transcriptase
inhibitors (efavirenz) or protease inhibitors (indinavir,
nelfinavir) and a crystal or a mixed crystal of compound A and the
like are evaluated by XTT method using CEM-SS cells infected with
HIV-1 IIIB.
[0304] In addition, the effect of combined use of three agents of a
crystal or a mixed crystal of compound A, zidovudine and
lamivudine, or a crystal or a mixed crystal of compound A,
tenofovir and lamivudine, and the like is evaluated.
[0305] Prior to the combined use test, IC.sub.50 and CC.sub.50 of
each pharmaceutical agent alone are measured. 5 concentrations of
pharmaceutical agent a and 9 concentrations of pharmaceutical agent
b, determined based on these results, are combined to evaluate the
effect of combined use of two agents. For combined use of three
agents, a high concentration pharmaceutical agent b and a
pharmaceutical agent c are mixed and pharmaceutical agent a and the
concentration are combined for evaluation.
[0306] The test results of the crystal or mixed crystal of compound
A and combination drug alone or in combination thereof are analyzed
based on the programs of Prichard and Shipman MacSynergy II version
2.01 and Deltagraph version 1.5d.
[0307] A three-dimensional plot is drawn from inhibition at the
concentrations of each combined pharmaceutical agent, obtained from
3 times of tests, with 95% (or 68%, 99%) confidence limits, and the
effect of the combined use is evaluated based on the numerical
values of .mu.M.sup.2% calculated therefrom. The criteria of
evaluation are shown in the following.
TABLE-US-00009 Definition of interaction .mu.m.sup.2 % Strong
synergistic action >100 Slight synergistic action +51-+100
Additive action +50--50 Slight antagonistic action -51--100 Strong
antagonistic action <-100
INDUSTRIAL FIELD OF UTILIZATION
[0308] The crystal of compound A of the present invention, which
has the above-mentioned particular crystal form, shows an anti-HIV
effect as well as superior crystal stability. Therefore, it is
useful as a starting material of a pharmaceutical composition,
particularly, various pharmaceutical compositions for the
prophylaxis and/or treatment of AIDS.
BRIEF DESCRIPTION OF THE DRAWINGS
[0309] FIG. 1 shows multiple records of X-ray powder diffraction
patterns, wherein the upper line shows the diffraction pattern of
crystal form III, the middle line shows the diffraction pattern of
crystal form I, the lower line shows the diffraction pattern of
crystal form II, the vertical axis shows diffraction intensity
(cps: counts per second: intervals of scale is 2500 cps) and the
transverse axis shows diffraction angle)2.theta.(.degree.).
[0310] FIG. 2 shows multiple records of X-ray powder diffraction
pattern obtained from the sample after 3-day preservation of the
stability test of crystal form I. For comparison, the uppermost
line shows the diffraction pattern (initial conditions) of crystal
form II, and the lowermost line shows the diffraction pattern
(initial conditions) of crystal form I. Shown from the second line
are diffraction patterns under preservation condition #6
(60.degree. C./75% R.H., open container, 3 weeks preservation),
preservation condition #4 (60.degree. C., container with stopper, 3
weeks preservation), preservation condition #5 (60.degree. C., open
container, 3 weeks preservation), preservation condition #3
(80.degree. C., open container, 3 days preservation) and
preservation condition #2 (80.degree. C., container with stopper, 3
days preservation). The vertical axis shows diffraction intensity
(cps: counts per second: intervals of scale is 2500 cps) and the
transverse axis shows diffraction angle)2.theta.(.degree.).
SEQUENCE LISTING FREE TEXT
[0311] SEQ ID; No 1: Donor + chain for determining HIV integrase
activity
[0312] SEQ ID; No 2: Donor - chain for determining HIV integrase
activity
[0313] SEQ ID; No 3: Target + chain for determining HIV integrase
activity
[0314] SEQ ID; No 4: Target - chain for determining HIV integrase
activity
[0315] The instant application includes a Statement Accompanying
Sequence Listing, and a Sequence Listing in both paper and
computer-readable formats.
Sequence CWU 1
1
4132DNAArtificial SequenceDonor plus strand for activity
determination of HIV integrase. 1acccttttag tcagtgtgga aaatctctag
ca 32231DNAArtificial SequenceDonor minus strand for activity
determination of HIV integrase. 2actgctagag attttccaca ctgactaaaa g
31320DNAArtificial SequenceTarget plus strand for activity
determination of HIV integrase. 3tgaccaaggg ctaattcact
20420DNAArtificial SequenceTarget minus strand for activity
determination of HIV integrase. 4agtgaattag cccttggtca 20
* * * * *